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Abstract
Despite modern treatment advances, overall survival (OS) remains poor for many
cancers such as liver and brain. Cancer is a fundamentally heterogeneous and adapt-
able disease and therefore personalized adaptive treatment strategies may be a key
towards improving OS. Radiotherapy, a commonly used cancer treatment technique
which employs ionizing radiation to kill tumours, holds promise for delivering adaptive
treatment. However, effective adaptation requires the ability to assess and predict
tumour treatment response. Therefore development of treatment response prediction
tools represents a critical first step towards improving patient outcomes via treatment
adaptation. The overall goal of this thesis is to develop treatment response prediction
methods with a view towards guiding adaptive radiotherapy.
First, we investigated the relationship between radiation dose and local tumour
control among patients with primary and metastatic colorectal liver tumours. We
established and compared their dose-response relationships and found that 84 Gy
and 95 Gy of radiation could provide 90% probabilities of 6-month local control for
the primary and metastatic groups respectively.
Tumour control most often cannot be improved simply through escalating the
dose to the entire tumour due to increased risk of side effects. However, it may be
possible to safely increase the dose to tumour sub-volumes. Therefore, the second
and third contributions of this thesis involve development of image-based treatment
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response prediction methods which are needed to identify tumour sub-volumes where
additional radiation should be deposited to improve tumour control.
Our second contribution involved augmenting a voxel-based method known as
parametric response mapping (PRM) to account for image registration error (IRE).
The augmented PRM helped to quantify and visualize IRE-related variability. In
our third contribution, we further generalized PRM to permit collective analysis of
multi-parametric image data. The proposed method was applied to multi-parametric
imaging from a patient cohort with glioblastoma and was found to predict OS ≥ 18
months (median OS) with a sensitivity and specificity of 90% and 78% respectively.
In summary, these contributions provided some of the response assessment ground-
work needed to guide adaptive RT. Image-based dose response relationships via the
augmented and multi-parametric response maps will facilitate personalization and
guidance of adaptive radiotherapy.
Keywords: treatment response prediction, adaptive radiotherapy, parametric response
mapping, multi-parametric imaging, image analysis, image registration error, dose re-
sponse modelling, principal component analysis, liver cancer, glioblastoma
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1Chapter 1
Introduction
1.1 Overview
Approximately 41% of females and 45% of males in Canada will develop cancer in
their lifetime [1]. Cancer is Canada’s leading cause of mortality accounting for ap-
proximately 30% of all deaths in 2014 [1]. While the age-adjusted incidence of cancer
has not increased in Canada in the past decade, the absolute number of new cases is
expected to continue rising due to the increasing age of the Canadian population [1].
Despite modern treatment advances, the overall prognosis remains poor for many
types of cancer such as liver, lung, brain, and late-stage disease [1, 2]. The hallmarks
of cancer identify it as a fundamentally heterogeneous and adaptable disease [3].
Consequently, the development of personalized treatment strategies which adapt to
heterogeneous tumour response may be a key towards improving survival and/or
quality of life.
The development of effective treatment response prediction represents a critical
first step towards implementing adaptive treatment strategies. If it is known how
a patient’s tumour is going to respond during the course of treatment, then this
information could be used to adapt treatments to further optimize tumour control
2and/or reduce treatment related side effects.
This thesis describes the development of treatment response prediction methods
with a view towards guiding adaptive radiotherapy. The present chapter provides
a brief introduction to cancer and its treatment (§1.2-1.4) focusing on strategies for
adaptive radiotherapy and image-based treatment response prediction (§1.5-1.7). The
overall goal of this work and research objectives are also presented within this chapter
(§1.9).
1.2 Cancer and the hallmarks of adaptation
Cancer is a group of related diseases including over one hundred different types [4].
World-wide the most common types of cancer among women are breast, colorectal,
lung, cervical, and stomach, and among men the most common types of cancer are
lung, prostate, colorectal, stomach, and liver [5]. Cancer has a diverse set of underly-
ing causes and suspected risk factors including but not limited to tobacco and alcohol
use, diet and obesity, radiation or carcinogen exposure, viral or bacterial infections
and hereditary factors [6, 7]. Cancer may also develop spontaneously without a direct
known cause. The development of cancer involves a series of genetic mutations which
lead to unrestrained cell growth and the ability of cells to metastasize to distant sites.
Ultimately, cancer causes morbidity and death through inhibiting the normal function
of aﬄicted organs or tissues.
In 2000, Hanahan and Weinberg proposed six common hallmarks of cancer with
the underlying idea that normal cells progressively evolve towards exhibiting these
traits during malignant transformation [3]. These traits included resisting cell death,
sustaining proliferative signalling, evading growth suppressors, activating invasion
and metastasis, enabling replicative immortality, and inducing angiogenesis. Since
3then, Hanahan and Weinberg have proposed two emerging hallmarks, deregulation of
cellular energetics and avoiding immune destruction, as well as two hallmark-enabling
characteristics, tumour promoting inflammation and genetic instability [8].
In aggregate, these traits identify cancer as a fundamentally heterogeneous and
adaptable disease. Sustained proliferative signalling, evasion of growth suppressors,
and the ability to grow new vasculature (angiogenesis) to deliver nutrients and re-
move waste products enable cancer to grow quickly and in a sustained manner. When
paired with genetic instability, this unrestrained proliferative capability amplifies and
sustains genetic diversity which supports cancer’s ability to adapt to selective pres-
sures from treatment, immune response, or the microenvironment.
1.3 Common treatment strategies and outcomes
1.3.1 Treatment strategies
A diverse array of strategies is available to treat cancer. Common treatment strategies
include surgery, chemotherapy, radiotherapy, or some combination of one or more of
these treatments.
Surgical removal can be particularly effective for patients that have a solitary well-
defined tumour such as in early stage lung, breast, or liver cancer [9–11]. Conversely,
surgery is often contraindicated for patients with advanced stage cancer where tu-
mours tend to be large, multi-focal, diffuse, or have metastasized to multiple sites.
Surgery is also not an option for blood-borne cancers such as lymphoma and leukemia
and for patients who are medically unfit to undergo general surgery.
Chemotherapy typically involves the oral or intravenous administration of chemi-
cal agents into the bloodstream or directly to the tumour. Depending on the specific
agent, tumour cell kill can be achieved in a number of different ways including but not
4limited to causing direct DNA damage and prevention or disruption of cell replication.
For example, temozolomide is an orally ingested chemotherapy agent used to treat
high-grade glioma that triggers cell death via DNA alkylation [12]. Chemotherapy is
used for treating systemic disease such as metastatic and blood-borne cancers and is
often used in combination with surgery or radiotherapy to eliminate residual or re-
current disease. Newer targeted drug therapies which are not commonly classified as
cytotoxic chemotherapy agents have also been developed. These novel therapies tar-
get certain cellular pathways that support tumour growth such as epidermal growth
factor and angiogenic pathways [13, 14].
Radiotherapy (RT) involves the use of ionizing radiation to kill tumours and
can be delivered externally via the use of linear accelerators (external beam RT) or
internally via the use of small radioactive seeds that are temporarily or permanently
implanted within the tumour. Radiation causes tumour cell death via direct and
indirect action on DNA. Direct action involves the direct interaction between incident
radiation and tumour cell DNA which can cause DNA chemical changes or breaks.
Indirect action involves the interaction of incident radiation with molecules other
than DNA within tumour cells (predominantly water molecules), resulting in the
production of reactive oxygen species which cause DNA damage through ionization
and the breaking of chemical bonds. Indirect action is estimated to account for
approximately two thirds of DNA damage caused by conventional external beam
gamma-ray radiation[15]. Since radiotherapy is a targeted therapy it is well-suited
towards treatment of solitary tumours which can be visualized via medical imaging
such as computed tomography (CT) or magnetic resonance imaging (MRI). RT is a
central theme within this thesis and so a more in-depth discussion of RT is provided
in the next section.
51.3.2 Outcomes
Survival and quality of life are typical cancer treatment outcomes that are measured.
Survival varies widely depending on cancer type. For example, 5-year relative overall
survival (OS) rates for two of the most common cancers, breast and prostate, have
been estimated to be 89% and 99% respectively independent of the stage at diagnosis.
In contrast, the same figures for liver and brain cancer (focuses of this thesis) are 18%
and 33% respectively [16]. Outcomes also vary depending on the stage of cancer at
diagnosis. For example, the 5-year OS rates for breast and prostate cancer drop to
25.9% and 28.2% respectively for the subset of patients with advanced stage disease
(e.g. distant metastases) [16].
Both patients who respond and do not respond to treatment may experience
treatment-related side-effects that can have a significant impact on their quality of
life. Depending on the cancer type, side effects could include things such as neurocog-
nitive impairment (brain), difficulty breathing (lung), sexual dysfunction (prostate),
urinary and fecal incontinence (bladder, colorectal), difficulty swallowing (head and
neck), poor cosmesis (breast), and infertility [17]. Side-effects place limits on the
amount of treatment that can be safely delivered to the patient without negatively
impacting their health or quality of life. For example, the dose of radiation that
can be safely prescribed to liver tumours is often constrained by the risk of causing
radiation induced liver disease [18].
In summary, despite favourable overall survival for some cancers, there remains a
strong need to develop new treatment strategies to improve overall outcomes includ-
ing survival and treatment related toxicities. In §1.4 and §1.5 we introduce RT in
more detail and discuss the case for implementing adaptive RT strategies to improve
treatment outcomes.
61.4 Radiotherapy
1.4.1 An overview of conventional radiotherapy
According to the National Cancer Institute (Bethesda MD), approximately half of all
cancer patients will receive some form of radiation therapy during their treatment [19].
There are several major steps in the external beam RT workflow which include CT
simulation, treatment planning, patient setup and treatment delivery. CT simulation
involves acquiring a CT scan of the patient (planning CT) with the patient positioned
in a way that simulates a reproducible treatment position. An RT plan detailing the
precise amount of radiation to be deposited throughout the patient is then generated
based on the planning CT using a treatment planning system. On treatment day, the
radiation therapist sets the patient up on the treatment couch so that they match
their position on the planning CT. The setup phase prior to treatment involves the
use of patient immobilization equipment and medical imaging devices either built in
or calibrated with the linear accelerator (e.g. on-board imaging) in order to improve
and verify the accuracy of patient positioning. Accurate setup is crucial for ensuring
that the RT plan is delivered to the correct location within the body. This prevents
geographic miss which would under-treat the tumour and over irradiate surrounding
normal tissues, leading to tumour recurrence and increased risks of treatment side
effects.
External beam RT uses a specially designed linear accelerator to generate and
deliver ionizing radiation. The RT plan is delivered in a series of treatment fractions
(e.g. one per day) over the course of several weeks. For example 60 Gray (unit of ab-
sorbed radiation dose, 1 Gy = 1 J/kg) of radiation is commonly delivered to patients
in 2 Gy fractions for a total of 30 fractions. The patient must return to the cancer
clinic for each fraction and be precisely positioned by the therapist each time. This
7fractionated approach takes advantage of tumour and normal tissue radiobiology in
order to increase tumour cell kill (improving tumour control) and decrease normal
tissue cell kill (decreasing side-effects) [15]. Fractionation allows time for the tumour
to become re-sensitized to radiation via re-oxygenation of hypoxic regions [15]. It
also allows time for some of the tumour cells which were previously in a radiation
insensitive phase of the cell-division cycle (e.g. S-phase) to eventually re-distribute
into more radiation sensitive phases of the cycle (e.g. G2 and M phases) [15]. Frac-
tionation helps to protect normal tissues by allowing time for normal tissue DNA
repair and for repopulation (replication) of normal tissue cells [15]. In §1.4.2 and
§1.4.3 we introduce RT in more detail and discuss the case for implementing adaptive
RT strategies to improve treatment outcomes.
1.4.2 Radiotherapy delivery techniques
There are a variety of RT delivery techniques available on modern linear accelerators
including but not limited to 3D conformal RT (3D-CRT), intensity-modulated RT
(IMRT), and stereotactic body RT (SBRT). For each technique, the angle, shape,
and intensity of radiation beams are selected in order to deliver a prescribed dose of
radiation to the tumour while minimizing the dose received by surrounding normal
tissues. Figure 1.1 shows an example of a modern linear accelerator.
Linear accelerators have a pair of moveable tungsten blocks (jaws) in the treat-
ment head which can be used to create rectangular shaped radiation fields. The
blocks provide an effective radiation shield due to tungsten’s high density and melt-
ing point. The multi-leaf collimator (MLC), which is composed of two large sets of
thin independently-controlled tungsten leaves, can then be used to further refine the
shape of radiation fields. Figure 1.2 provides a view of the MLC along the direction
of the beam. On board imaging (e.g. portal imager, cone-beam CT) is attached to
8Figure 1.1: Modern linear accelerator with on board imaging (cone-beam CT).
Figure 1.2: A view of the multi-leaf collimator within the treatment head of the linear
accelerator. Each tungsten leaf can be moved independently to create unique shapes
blocking all or part of the beam.
9the linear accelerator. The entire linear accelerator can be rotated around the patient
to permit multiple beam delivery and imaging angles.
Intensity-modulated RT (IMRT) is a more modern technique that uses multiple
MLC shapes at each beam angle in order to create complex non-uniform intensity
beams. Each shape blocks and exposes different parts of the tumour and surround-
ing normal tissue. Sophisticated optimization algorithms are used to determine the
specific MLC shapes that must be used at each angle in order to meet a set of plan-
ning objectives specified by the user. Objectives could include constraints on the
uniformity and magnitude of radiation delivered to the tumour and normal tissues.
Figure 1.3 illustrates an example IMRT dose distribution for treatment of glioblas-
toma which is one of the types of cancer that we will address in this thesis. The
visible gross tumour volume (GTV) is shown in pink. The GTV is then expanded by
a spatial margin to account for disease spread that is not visible on imaging. This
expansion is constrained by anatomic boundaries to disease spread such as the skull in
the example from 1.3. The resulting region, called the clinical target volume (CTV),
encompasses the GTV and is shown in green. For glioblastomas, the CTV is much
larger than the GTV since glioblastoma tumours are highly invasive and tumour out-
growths are known to occupy a large region around the visible tumour. Finally, the
CTV is expanded by another margin to account for treatment delivery uncertainties
such as setup error. This region is called the planning target volume (PTV). Three
levels of radiation dose are shown as isodose lines.
The overall goal of RT is to deliver a high uniform dose of radiation to the target
(i.e. to the PTV) while limiting the dose received by critical structures. In this
example the PTV is immediately adjacent to a critical structure (brainstem). Due to
the ability of IMRT to produce conformal dose distributions with steep dose gradients,
the brainstem receives substantially less radiation than the PTV. Similarly, the lenses
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Figure 1.3: Axial view of a radiation dose distribution for an IMRT glioblastoma treat-
ment. Radiation dose deposited within the head is indicated by the thick coloured
lines and the dose legend in the top left corner.
of the eye, optic nerves, and contralateral hippocampus are spared.
Stereotactic body RT (SBRT) is a technique which involves delivering a patient’s
entire treatment in a small number of high-dose fractions (e.g. 5-6). SBRT often
uses intensity-modulation and requires precise image-guidance in order to ensure that
surrounding normal tissues are not exposed to the high doses of radiation that are
delivered in each fraction. SBRT is a common technique for treatment of liver and
lung and is an important topic discussed further in Chapter 2 where we investigate
the relationship between tumour control and radiation dose for liver tumour SBRT.
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1.4.3 Key challenges and the case for adaptive radiotherapy
The overall goal of curative-intent cancer treatment is to maximize tumour control
while minimizing treatment-related side effects. Conventionally, RT tries to accom-
plish this goal by delivering a high uniform dose of radiation to the tumour while
minimizing the dose received by surrounding healthy tissues. However, there are
several key challenges to this approach which support the case for developing person-
alized adaptive RT strategies. Four challenges are broadly described below and this
thesis will address two of these challenges.
1) Determination of ideal dose prescriptions
The relationship between the radiation dose fractionation (particularly SBRT)
and the resulting tumour control, as well as the associated treatment side-effects may
not always be well-understood. Therefore, in some cases, it can be unclear about the
trade-offs between tumour control and normal tissue toxicities. This equivocation is
particularly challenging for cancers with poor outcomes or for late-stage disease where
patients are declining in health with no curative intent treatment options available. In
cases where the disease is localized, RT may be able to substantially assist in survival
and improve quality of life. Liver cancer provides an instructive example where there
is a risk of radiation induced liver disease (RILD) [18]. The risk of RILD is related
to the size of the tumour relative to the rest of the healthy liver. On the other hand,
sufficient dose must be given to control the tumour. Therefore, the resulting cost-
benefit analysis between tumour control and RILD is patient-specific. Determining
the radiation doses required to effectively control liver tumours is one of the focuses
of this thesis.
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2) Motion management during treatment
Voluntary and involuntary patient motion during treatment can cause radiation
to be deposited where it is not intended, decreasing the dose received by the tumour
and increasing the dose received by normal tissues. Dose can be delivered to larger
regions which encompass the tumour motion, however this also increases the dose
received by normal tissues. This in turn may decrease the overall radiation dose that
can be prescribed to the tumour. Lung and liver tumours provide examples where
motion is a challenge. Lung and liver tumours are influenced by respiratory motion
and in two small studies have been shown to move an average of 12 mm ± 2 mm and
9 mm ± 5 mm in the superior-inferior directions respectively [20, 21]. This motion
is patient-specific, pseudo-periodic, and may or may not be consistent throughout
treatment [20, 21].
A variety of techniques have been developed to manage breathing-related tumour
motion. Keall et al. [22] provide a comprehensive review of current clinical motion
management strategies. Some of the most common techniques include immobilization,
breath-hold, active breathing control, and gating. Adapting radiation delivery to inter
and intra-fraction patient motion is a key aspect of current clinical practice and is
typically referred to as image-guided RT (IGRT).
3) Geometric adaptation
Tumours may change size and patients may gain or lose weight during treat-
ment. For example, one study found that head and neck tumours shrink by a median
of 69.5% in volume during RT [23]. As a result of these intra-treatment changes,
the planning CT may no longer accurately represent the anatomy of the patient.
Therefore the RT plan, which is based on the pre-treatment planning CT, may be-
come sub-optimal leading to patient-specific changes in the dose received by the tu-
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mour and surrounding normal tissues. Adaptive re-planning has been implemented
whereby patients undergo one or more planning CT scans throughout treatment and
the treatment plan is updated according to large tumour and anatomical changes
[24]. Adaptive re-planning based on volumetric tumour and anatomical changes has
been investigated for head and neck, lung, bladder, and prostate cancers in the clinic
[24–30].
4) Functional adaptation
Finally, as discussed in §1.2, cancer is a fundamentally heterogeneous and adapt-
able disease. Significant genetic variation exists between different tumour types, be-
tween tumours of the same type, and even between different cells within a single
tumour [31]. Currently, different treatment regimens are applied to different tumour
types, addressing a portion of this variability. However, standardized treatment pro-
tocols are applied to tumours of the same type and therefore inter-patient variability
is not addressed. Moreover, tumours are usually targeted with a uniform dose of
radiation which cannot address intra-tumour variability. Different sub-regions within
a tumour can be more or less sensitive to radiation depending on factors like cycling
hypoxia and local oxygen concentration [32]. These factors can also change through-
out the course of treatment. Therefore the use of standardized uniform doses may not
maximize tumour control for individual patients. While adaptation due to volumetric
changes in tumours is being practiced in the clinic, adaptation to intra-tumour het-
erogeneity has not yet entered the clinic. This thesis investigates and develops tools
to support this goal.
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In summary, key challenges in conventional RT relate to the application of the
same treatment plan throughout the fractionated treatment course. Cancer represents
a heterogeneous and adaptable disease which may necessitate personalized adaptive
treatment strategies in order to maximize tumour control and minimize treatment-
related side-effects. RT is particularly well suited towards adaptive implementations
since treatment fractionation provides multiple opportunities to evaluate and adapt
during the treatment course. RT is already an image-guided localized treatment and
so has the potential to adapt to local variability. However, personalized adaptive
RT requires additional resources and conventional standardized RT already provides
favourable outcomes for many cancers. Therefore investigation of adaptive strategies
may be best suited to disease contexts with relatively poor outcomes such as short
survival or high toxicities.
This thesis focuses on personalized dose-prescription (the first challenge) and using
functional imaging to assess tumour response to guide RT adaptation (the fourth
challenge). Current and emerging adaptive RT strategies related to these challenges
are described in the next section.
1.5 Strategies for adaptive radiotherapy
1.5.1 Adapting radiation dose prescriptions to patients
The full relationship between the amount of radiation delivered and tumour control
is less well-understood than for normal tissue complications. However, substantial
effort has been undertaken to try to define normal tissue dose limits beyond which
unacceptable side-effects are expected to occur. For example, a dose of 59 Gy to 1-10
cc of the brain stem is associated with a 5% rate of permanent cranial neuropathy
[33]. Similarly, dose-volume constraints have been defined for many other critical
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structures including but not limited to the brain, spinal cord, rectum, bladder, lungs,
liver, and heart [33]. These normal tissue dose constraints are then incorporated
into treatment planning to ensure that side-effect severity is minimized. Constraint-
based planning is a fundamental part of current clinical practice which helps to adapt
standardized dose prescriptions to the anatomy of different patients.
Less commonly, normal tissue complication probability (NTCP) models may be
integrated into clinical practice. These models seek to predict the probability that a
patient will develop a specific side effect as a function of the dose received by a normal
tissue of interest. For example, Dawson et al. [18] modelled the probability that a
patient would develop radiation induced liver disease (RILD) less than 4 months
after RT. The dose prescribed to liver tumours can then be adapted to individual
patients based on managing their risk of developing RILD according to the NTCP
model [34, 35]. This particular NTCP model plays an important role in Chapter 2
of this thesis. Marks et al. [33] provide an excellent overview of NTCP models used
in the clinic. The Lyman-Kutcher-Burman NTCP model [36, 37] is among the most
commonly used methods and is described by the following three equations;
NTCP =
1√
2pi
∫ t
−∞
e−
x2
2 dx (1.1)
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mTD50
(1.2)
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∑
i
viD
1
n
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n (1.3)
The EUD (equivalent uniform dose) summarizes the non-uniform normal tissue dose
distribution. TD50 describes the uniform dose that when received by the normal
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tissue of interest would elicit a 50% probability of a side-effect. m controls the slope
of the NTCP curve and n describes how much the NTCP is influenced by the volume
of irradiated normal tissue. Di represents the dose received by a fractional volume vi
of the normal tissue of interest. The model is then fit to the dose and complication
data amongst a group of patients to determine the TD50, m, and n model parameters.
Figure 1.4 provides an example of a typical sigmoidal NTCP model curve.
Figure 1.4: Example of a typical sigmoidal NTCP model for a fictional side-effect
with TD50 = 35 Gy.
Similar to normal tissue, tumour control probability (TCP) models have also been
developed which seek to predict the probability of tumour response at some time post-
RT as a function of the dose received by the tumour. For example, Chang et al. [38]
modelled the probability of tumour local control at 1 year post-treatment for patients
treated for colorectal liver metastases. Many different models have been investigated
and a review is provided by O’Rourke et al. [39]. The logistic TCP model [40] is a
commonly used approach and is described by
TCP =
1
1 + (D50/D)k
(1.4)
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where D represents the dose received by the tumour, D50 represents the dose required
to elicit a 50% probability of tumour control, and k controls the slope of the TCP
curve at D50. The model parameters D50 and k are then acquired by fitting the model
to patient tumour dose and control data.
Together, NTCP and TCP model the relationship between radiation dose, tumour
control and treatment side-effects. Knowledge of these relationships can then be used
prospectively during treatment planning to adapt prescription doses in an effort to
maximize the cost-benefit ratio for individual patients. Liver NTCP models have been
previously established [18]. However, liver tumour irradiation has only recently been
enabled through advances in radiation targeting (e.g. IMRT, image-guidance) which
can reduce the risk of radiation-induced liver disease to acceptable levels. Therefore
liver TCP is not as well-understood as liver NTCP and is the focus of Chapter 2.
1.5.2 Adapting dose distributions to intra-tumour hetero-
geneity
Significant genetic variation exists within individual tumours and different tumour
sub-regions can be more or less sensitive to radiation depending on temporally varying
factors like hypoxia and local oxygen concentration [31, 32]. Sub-volume boosting and
dose-painting-by-numbers strategies have been proposed to address this variability in
order to improve tumour control and decrease side-effects [41].
Sub-volume boosting typically involves escalating the dose delivered to a suspected
radio-resistant tumour sub-region by a fixed amount where resistance is assessed using
functional imaging (assessment discussed further below). In contrast, dose-painting-
by-numbers involves continuous modulation of the dose throughout the entire tumour
according to local radio-sensitivity. Regions suspected to be more radio-resistant re-
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ceive more dose and radio-sensitive regions receive less dose. Sub-volume boosting is
the simpler of the two techniques as it can be readily implemented using clinically
available treatment planning systems. This is because clinical treatment planning
systems are already adept at creating plans which meet discrete dose objectives for
well-defined regions of interest. In contrast, dose-painting by numbers requires more
sophisticated treatment planning optimization algorithms which can meet a contin-
uum of dose objectives within the tumour. This approach requires more precise
radiation delivery since the radiation dose is modulated within the tumour on a finer
spatial scale and has yet to be tested clinically for its feasibility. For both approaches,
tumour radio-resistance could be re-assessed during treatment to monitor and adapt
to temporal variation. Figure 1.5 demonstrates the difference between sub-volume
boosting and dose painting by numbers using a mock tumour example.
Figure 1.5: Mock tumour example (circle) illustrating the differences between sub-
volume boosting and dose-painting by numbers with respect to radiation dose depo-
sition. Dmin and Dmax refer to the minimum and maximum dose prescribed to the
tumour where Dmin is the conventionally delivered dose and Dmax is the maximum
boost dose.
These next-generation adaptive RT techniques represent a personalized and adap-
tive approach to RT. Due to dose constraints imposed by normal tissues, only a fi-
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nite amount of radiation can be delivered to a patient. Therefore the overall goal
is to use this radiation as efficiently as possible by exploiting variability in tumour
radio-sensitivity. However, a key challenge to this approach is obtaining reliable mea-
sures of radio-sensitivity that have been linked to clinical tumour control outcomes.
Novel imaging biomarkers are needed which indicate regional tumour sensitivity or
predict which parts of the tumour are responding or progressing during treatment.
Feasibility studies have focused on the use of various positron emission tomography
(PET) image markers of hypoxia such as F18-fluorazomycin arabinoside (FAZA) and
F18-fluromisonidazole (FMISO), or markers of cell proliferation such as C11-choline
[42–47]. Hypoxia has been used as surrogate for local radio-sensitivity since low oxy-
gen conditions inhibit radiation-induced production of free radicals thereby reducing
tumour cell DNA damage and death. Alternatively, cell proliferation has been used
as a surrogate for local tumour progression.
Next-generation adaptive RT techniques are resource intensive and require IMRT,
image-guidance, functional imaging, image processing and non-commercially available
treatment planning algorithms. To date, research into these methods has focused
mainly on technical feasibility [42–47]. However a few dose-painting studies have
been performed with prospective application to patients with head and neck cancer
[48, 49]. Preliminary modelling and feasibility studies as reviewed by Bentzen et al.
[41] predict gains of 50% or more in tumour control probability, suggesting that signif-
icant patient benefit could be derived from development of next-generation adaptive
RT techniques. However, clinical trials are still needed to verify whether targeting
resistant or proliferative tumour sub-regions actually provides the predicted benefit
in practice.
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1.6 Evaluation of treatment response and the need
for radiotherapy response prediction
Next generation adaptive RT will be enabled by effective image-based treatment
response prediction. Here we discuss current clinical methods for evaluating treatment
response and motivate the need for treatment response prediction (a focus of this
thesis) to support adaptive RT strategies.
1.6.1 Radiotherapy response evaluation in the clinic
Since RT is a localized treatment technique, evaluation of post-treatment changes
in tumour size is a commonly used treatment response metric. Decreases in tumour
size may indicate a favourable response and increases in tumour size may indicate
tumour progression. The response evaluation criteria in solid tumours (RECIST)
were initially proposed in 2000 and revised in 2009 to provide a standardized way of
assessing and describing treatment response using changes in tumour size [50].
The RECIST criteria are comprehensive and include many special considerations.
The main elements can be summarized as follows. Complete response is defined as the
complete disappearance of all targeted lesions. Partial response is defined as at least
a 30% decrease in the sum of the diameters of all of the target lesions with respect
to pre-treatment baseline measurements. Progressive disease is defined as at least a
20% increase in the sum of the diameters of the target lesions, or by the appearance
of new lesions. Stable disease is defined by changes that do not meet the criteria for
complete response, partial response, or progressive disease. The tumour diameters
are defined by the long-axis of each tumour. That is, the longest straight-line tumour
diameters that can be measured are used to assess response. Figure 1.6 provides an
example of RECIST measurement for a glioblastoma tumour.
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Figure 1.6: Example RECIST measurements for a glioblastoma tumour on baseline
and follow-up contrast-enhanced T1-weighted MRI scans. A 33% increase in tumour
diameter identifies this patient as having progressive disease according to the RECIST
criteria
Blood-based measurements of specific proteins have also been used to evalu-
ate treatment response and progression. For example, alpha-fetoprotein, carcino-
embyronic antigen, and prostate-specific antigen levels are often measured for hepa-
tocellular carcinoma, colorectal cancer, and prostate cancer respectively [51–55]. De-
creased levels compared to pre-treatment measurements may indicate response and
increased levels may indicate progression or recurrence.
1.6.2 The need for radiotherapy response prediction
The central idea behind next-generation adaptive RT is to adapt treatment to pre-
dictions of patient-specific tumour response to radiation. RECIST provides a useful
framework for treatment response evaluation however it is not well-suited towards
guiding these techniques. RECIST measurements indicate the trajectory of tumour
size changes but can be confounded by factors such as radiation injury, edema and
transient tumour size increases known as pseudo-progression [56, 57]. RECIST cut-off
values are designed to document gross tumour changes (progression, partial response,
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complete response), thus limiting descriptive and predictive utility particularly early
on in treatment when such changes may not yet have occurred. Finally, and most
importantly, RECIST does not indicate which parts of the tumour will respond or
progress during or after treatment.
Ideally, techniques are needed which can predict tumour response before or dur-
ing treatment. Early treatment response prediction could enable efficient adaptation
without the need for additional treatment and risk of additional side-effects. On a
rudimentary level, TCP modelling attempts to predict overall tumour response prior
to treatment based on proposed prescription doses. However, next generation adap-
tive RT requires the ability to predict response throughout the tumour in order to help
define the shape and intensity of radiation beams. Therefore image-based biomarkers
of early treatment response are needed for guiding adaptive treatment. Such image-
based biomarkers are identified through explicit correlations with treatment outcomes
and a variety of different imaging parameters can be investigated for predictive po-
tential. For example, it is well-known that hypoxia limits the effectiveness of RT
[32], therefore PET-based hypoxia imaging has been used in previous adaptive RT
studies as a direct surrogate for radio-resistance [42–44]. Image processing techniques
can also be exploited to mine other types of image data for predictive trends that
may not be as intuitive as hypoxia-imaging. Indeed, Bentzen, a key authority on
dose-painting research has commented that [41]:
“Validation of a dose painting target does not necessarily require a mech-
anistic understanding of the relationship between dose response and ex-
pression of the target. It is a sufficient and from a bioethical standpoint
probably also a necessary condition that an empirical relationship has
been demonstrated between target expression and worse local outcome of
radiation therapy.”
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Here, Bentzen reasoned that prediction of treatment-resistant regions of tumours (i.e.
dose painting targets) does not need to be verified through understanding the physio-
logical cause of that resistance. Rather, it must be validated that predicted resistance
leads to tumour recurrence in order to ethically justify the costs associated with the
delivery of modified or additional radiation treatments to the patient. Therefore
treatment response prediction via image-analysis techniques such as those presented
in this thesis is well-suited for defining dose-painting targets. Such image analysis
driven techniques can yield predictive trends that may not have a known mechanistic
explanation. However, the associated predictions are data driven and so efficacy is
demonstrated through verifying empirical relationships with treatment outcome.
In summary, image-based biomarkers of early treatment response are a necessary
and critical component in the development of next-generation adaptive RT strategies.
This is a central concept within this thesis and motivates the investigations in Chap-
ters 3 and 4 of this thesis. In the next section we discuss some of the fundamentals
of image based treatment response prediction including image analysis and imaging
methods.
1.7 Image-based treatment response prediction
An image allows us to visualize a two-dimensional array of numbers corresponding to
some physical property that has been measured by an imaging device. For example,
each pixel within a functional image can depict “blood volume” representing the
volume of blood supplied (millilitres per unit mass) within that pixel. Each number
in the corresponding image array is represented by a different shade of gray or colour
within the image permitting visualization of higher and lower blood volume regions
within the image. Figure 1.7 provides an artificial example of a blood volume image
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Figure 1.7: Artificial blood volume functional image with its corresponding image
array. The image array depicts the volume of blood estimated within each pixel and
is expressed in millilitres of blood per 100 grams of tissue.
along with its corresponding image array.
Image-based treatment response prediction involves analyzing the arrays of num-
bers that underlie images. For example, baseline functional images acquired before
treatment can be analyzed or comparisons can be made between images acquired be-
fore and after treatment. 3-dimensional image volumes can also be analyzed and are
defined by 3-dimensional arrays of numbers with each value in the array representing
a quantity measured for a small volume of tissue (voxel).
Many different types of imaging have been analyzed for biomarkers of treatment
response using a wide spectrum of image analysis techniques. These techniques are
often customized to the specific image data being analyzed and can range from di-
rect utilization of image intensity values to more complex methods involving machine
learning [57–59]. Consequently, a comprehensive review is beyond the scope of this
thesis. However this section will provide a brief overview of the image analysis con-
cepts involved in image-based treatment response prediction. Imaging methods which
are actively being investigated for predictive utility will also be discussed. The fol-
lowing discussion is divided into treatment response prediction via region-based and
voxel-based image analyses, both of which are employed within this thesis.
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1.7.1 Region based image analysis
Region-based analysis involves summarizing the image intensity values (image array
numbers) within a region of interest prior to searching for correlations with treat-
ment response. For example, the average image intensity within a tumour could be
computed for multiple patients. These values could then be found to be significantly
different between responding and non-responding patients and subsequently used to
predict outcome. Other descriptive summary statistics could also be investigated
such as the standard deviation, median, or inter-quartile range of the tumour inten-
sity values. Figure 1.8 provides an example of a region-based analysis of the artificial
blood volume image shown in figure 1.7.
A common approach involves acquisition of multiple images of the patient at dif-
ferent times (i.e. longitudinal imaging). Differences in tumour summary statistics
can then be investigated for correlations with outcome. For example images can be
acquired before and after treatment and then the change in the average image inten-
sities within the tumour can be determined. Increases or decreases in average image
intensity could then be found to relate to treatment response or tumour progression.
As demonstrated in figure 1.8, a potential limitation of region-based image analysis
is that global summary measures can be confounded by image intensity heterogeneity
within the tumour. For example, blood volume increases in one region of the tumour
could be offset by decreases in another region resulting in no change in average tumour
blood volume. For the purposes of prediction, such a patient could then be considered
to be the same as a patient with no change in tumour blood volume. In such examples,
differences in variability measures (e.g. standard deviation) may be more instructive.
Region-based methods can only be used to predict global measures of treatment
response such as overall survival and cannot be used to predict which parts of the
tumour are responding or progressing. Only global measures which summarize the
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Figure 1.8: Example of a region-based image analysis of two longitudinally acquired
blood volume images. The parameters µ and λ represent the mean and standard
deviation of the image intensity values within the red regions of interest respectively.
detailed voxel-wise image intensity changes within the tumour (e.g. mean values)
are available for prediction. These single-valued measures do not specify the image
intensity characteristics or changes of each tumour voxel and therefore cannot be
used to predict differential response between different parts of the tumour. The focus
of the next section is voxel-based image analysis which has potential for predicting
differential response within tumours.
1.7.2 Voxel based image analysis
Voxel-based image analysis takes image heterogeneity into account and can therefore
be more sensitive to changes than region-based methods. However, voxel-based meth-
ods are more complicated and can be influenced by additional sources of uncertainty.
One common approach towards voxel-based image analysis involves acquisition
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of longitudinal imaging for each patient which is then spatially aligned using image
registration algorithms [60]. After alignment, voxel values in one image can be com-
pared to the intensity of the spatially corresponding voxels in another image. With
this approach, localized intra-tumour changes in image intensity can be interrogated
for markers of treatment response. However, residual image registration error (align-
ment error) introduces variability into the analysis [61]. In the presence of image
registration error, voxels in one image may be incorrectly associated with voxels in
the neighbourhood around the spatially corresponding voxels in the other images.
Depending on the heterogeneity in the images, neighbouring voxels may or may not
have intensities that are similar to the spatially corresponding voxels and therefore
image registration error may introduce errors into subsequent analyses. Figure 1.9
provides a simple example of voxel-based image analysis without image registration
error.
More sophisticated analyses can also be performed which involve investigating im-
age texture in one or more images. Many different image texture features can be cal-
culated [62]. Each feature describes a different aspect of the relationship between the
intensities of neighbouring voxels and therefore provides a measure of the image het-
erogeneity. This information can then be fed into machine learning algorithms which
build classifiers for treatment response or tumour progression via pattern recognition
[58, 63]. The central idea is that progressing or responding tumours may exhibit char-
acteristic image textures which, if identified, can be used to identify patients which
may not be responding to treatment.
Voxel-based image analysis is necessary in order to predict which regions within a
tumour are responding and which regions are progressing (i.e. voxel-wise treatment
response). However to date, these methods have almost exclusively been applied to
improve prediction of global measures of treatment response (e.g. overall survival,
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Figure 1.9: Example of voxel-based image analysis where patient motion (10 degree
rotation) must be corrected using image registration.
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RECIST criteria). Current voxel-wise treatment response prediction studies have
focused on the use of imaging to define input parameters for mathematical models
of tumour growth [64–66]. Therefore prediction of voxel-wise treatment response via
direct analysis of imaging represents largely uncharted territory in current treatment
response prediction literature.
1.7.3 Imaging
While prediction of voxel-wise treatment response has yet to be pursued, many dif-
ferent types of imaging have been investigated for biomarkers of treatment response
of the entire tumour [67]. Typically, imaging which measures some aspect of tu-
mour function or of the tumour micro-environment is analyzed. Changes in these
measurements can then be monitored and analyzed over time to predict treatment
response.
Diffusion and perfusion-weighted magnetic resonance imaging (MRI) are com-
monly investigated for predictive potential [67, 68] and are also analyzed in Chapter
4 of this thesis. Diffusion-weighted imaging (DWI) measures the ability of water
molecules to diffuse in each voxel of tissue and provides a surrogate measure of local
cellular density. Tumours tend to exhibit restricted diffusion due to increased cellu-
lar density and so increases in diffusion after treatment could indicate response and
decreases could indicate progression. Perfusion-weighted imaging (PWI) provides a
measure of hemodynamic quantities such as blood flow and blood volume within each
voxel. Tumours may exhibit elevated blood volume compared to normal tissue due to
their ability to stimulate angiogenesis (growth of new vasculature) to support rapid
growth. Therefore increases in blood volume after treatment could indicate tumour
progression and decreases could indicate response. Figure 1.10 provides an example
of apparent diffusion coefficient (ADC) and relative cerebral blood volume (rCBV)
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maps derived from DWI and PWI imaging respectively. rCBV maps are expressed
in relative units with respect to the blood volume measured in healthy white mat-
ter. Dynamic contrast-enhanced ultrasound (DCE-US) and CT (DCE-CT) can also
be used to measure hemodynamic quantities and have been similarly investigated in
treatment response prediction studies [67, 69]. In this thesis we used blood volume
(BV) images derived from DCE-CT in Chapter 3 and investigated response prediction
using MRI-derived ADC and rCBV images in Chapter 4.
Figure 1.10: Example ADC and rCBV maps derived from diffusion and perfusion
weighted MR imaging acquired from a patient with glioblastoma at 1 and 3 months
post-radiotherapy. Contrast-enhanced T1-weighted images are also shown to indicate
the location of the tumour. ADC maps are expressed in units of 10−3 mm2/s and
rCBV maps are expressed in relative units with respect to the blood volume in white
matter.
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1.8 Summary
Cancer is heterogeneous and adaptable due to its characteristic genetic instability
and unrestrained growth. Genetic variability exists between different tumour types,
tumours of the same type and within individual tumours. This heterogeneity in turn
leads to variability in treatment efficacy not only between patients but potentially
within different sub-regions of individual tumours. Therefore, personalized treatment
strategies which can evaluate and adapt to heterogeneity in tumour response may be
a key towards improving tumour control and reducing treatment-related side-effects.
RT is a commonly used cancer treatment technique which uses ionizing radiation.
RT is well-suited towards adaptive implementations since intensity modulation and
image guidance can enable localized modification of treatment plans within the tu-
mour region (e.g. sub-volume boosting). RT is also delivered in multiple fractions
providing multiple opportunities to evaluate and adapt to variable tumour response.
Consequently, personalized adaptive RT is an active area of research which may have
potential for improving outcomes. Development of effective early treatment response
prediction constitutes a critical step towards implementation of personalized cancer
treatment strategies such as adaptive RT. In particular, image-based treatment re-
sponse evaluation methods which can predict voxel-wise tumour response are needed
to guide next generation adaptive RT techniques such as sub-volume boosting and
dose-painting by numbers.
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1.9 Thesis objectives
There is a strong theoretical basis for improving patient outcomes via the development
of personalized adaptive RT strategies. However, implementation of these strategies
directly depends on effective treatment response prediction software tools. The overall
goal of this thesis is to contribute to the development of treatment response prediction
methods to support future implementation of adaptive RT techniques. There are three
main objectives which correspond to Chapters 2, 3, and 4 respectively.
Objective 1 - Investigate and model the relationship between the probability of tumour
control and prescribed radiation dose for patients with liver tumours.
Objective 2 - Augment an image-based treatment response prediction method to
incorporate uncertainties due to unavoidable image registration error and to facilitate
identification of adaptive RT targets.
Objective 3 Develop a generalized image-based treatment response prediction frame-
work which enables improved analysis of multi-parametric image data.
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Chapter 2
Determination and comparison of
radiotherapy dose responses for
hepatocellular carcinoma and metastatic
colorectal liver tumours ∗
2.1 Introduction
Hepatocellular carcinoma (HCC) is the fourth most common cancer worldwide [1].
The liver is also the most common site of metastasis from colorectal carcinoma, with
the incidence of liver metastases exceeding 25% [2, 3]. Although transplantation and
surgical resection offer significant survival benefits among these two groups [4–7], im-
paired liver function, tumour size and the number of lesions can limit a patient’s
eligibility for these treatments. Consequently, there has been a push to develop al-
ternative locoregional therapies for treatment of primary and metastatic liver cancer.
Stereotactic body radiotherapy (SBRT) has shown promise as a new method to
∗This chapter has been previously published as Lausch et al. Determination and comparison of
radiotherapy dose responses for hepatocellular carcinoma and metastatic colorectal liver tumours.
Br. J. Radiol., 2013;85:20130147.
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safely and non-invasively treat liver tumours [8–11]. SBRT involves precise image-
guided delivery of a high dose of radiation to the tumour in a small number of fractions
and usually employs motion suppression or gating techniques. A positive association
between outcome and dose has previously been reported [11–13]. However, unlike
other tumour sites [14–18], there is currently a paucity of explicit liver tumour dose-
response modelling within the literature [11]. An improved understanding of radiation
dose response is necessary to help better inform future dose prescriptions.
At our institution, patients with liver lesions are prescribed the highest possi-
ble radiation dose while maintaining < 5% normal tissue complication probability
(NTCP) with respect to an end point of ≥ grade 3 Radiation Therapy Oncology
Group (RTOG) radiation-induced liver disease (RILD) [19]. As a result, patients are
treated with different doses depending on their tumour size relative to the size of
remaining healthy liver. This provides for a valuable opportunity to investigate the
dose response and to determine the radiation dose required to control liver tumours.
Here, our primary goal is to retrospectively determine separate dose-response
relationships for patients with HCC and metastatic (MET) colorectal liver tumours
using tumour control probability (TCP) modelling. Our secondary goal is to evaluate
local control rates between these two groups at our institution.
2.2 Patients and Methods
2.2.1 Patient data
The records of patients treated with radiotherapy (RT) at our institution for HCC
or MET colorectal liver tumours from 2004 to 2011 were reviewed. Patients who had
previous regional or systemic therapy were included in the analysis as long as their
treatment concluded prior to the start of RT. Patients who underwent additional
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concurrent therapy were excluded from the study. Patients who received alternative
therapy, post RT, were included; however, their follow-up data were censored on ini-
tiation of the additional therapy. No limit was placed on the size or the number of
target lesions. A total of 36 patients treated for HCC and 26 patients treated for MET
colorectal liver tumours were analysed. Follow-up data typically included CT-based
measurements of tumour size and measurements of α-fetoprotein (AFP) and carcino-
embryonic antigen (CEA) biomarkers. The times of all follow-up observations (i.e.
follow-up schedule) were reported with respect to the treatment end date and were
typically at 1 month, 3 months, 6 months, 1 year and 2 years after treatment. How-
ever, patient-specific scheduling challenges introduced variability into actual follow-up
dates and some tumour response measurements were assessed in between the afore-
mentioned time points. Patients’ data were collected, quality assured and analysed
in a database approved by our Institutional Review Board (Health Sciences REB#:
16487E).
2.2.2 Radiotherapy
The clinical target volume (CTV) was defined based on four dimensional CT scans.
Motion management involved patient immobilisation (Vac-Lok; CIVCO Medical Sys-
tems, Orange City, IA) and respiratory gating (Varian Real-Time Position Manage-
ment; Varian Medical Systems, Inc., Palo Alto, CA) to minimise internal motion.
Depending on patient motion and residual motion measurements, an additional 2-10-
mm, 3-25-mm and 3-7-mm planning target volume (PTV) margin was added to the
CTV in the anterior-posterior, superior- inferior and lateral directions, respectively.
Patients were treated with three-dimensional conformal RT, intensity-modulated ra-
diotherapy or tomotherapy.
Diverse dose fractionation regimens were employed in the two patient groups,
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including both traditional and hypofractionation schedules. The dose prescribed to
each patient was maximised while maintaining < 5% Lyman-Kutcher NTCP for the
remaining healthy liver with respect to an end point of grade 3 or higher RTOG RILD
[19], and while maintaining the dose to other organs at risk to acceptable levels. The
NTCP model employed parameter values reported by Dawson et al. [19], who had
separate parameter sets for calculating the probability of liver toxicity between HCC
and MET patient groups. Doses were prescribed to the PTV, such that 95% of the
PTV received at least 95% of the prescribed dose. The maximum PTV dose was
typically limited to no more than 107% of the prescribed dose. Consequently, the
PTV mean dose was similar to the prescribed dose. The doses received by the small
bowel, lung, heart, stomach, kidneys and spinal cord were also constrained to prevent
toxicity.
2.2.3 Tumour control probability
A TCP model was used to investigate the relationship between the radiation dose and
the tumour control. 6-month local control was chosen as the end point for the TCP
model as detailed 6-month local control data were available for the largest number of
patients and were considered clinically important a priori. Patients who had failed
locally or died owing to liver disease progression prior to the 6-month time point
were considered to be uncontrolled at 6 months. Since the patients included in this
study were treated with diverse dose-fractionation regimens, prescription doses were
converted to 2 Gy per fraction equivalent doses prior to TCP modelling to ensure
biological comparability. Equivalent doses were computed using the standard linear
quadratic model (LQM) approach [20].
Briefly, the LQM defines the number of radiation-induced cell-lethal events (i.e.
double-strand DNA breaks) due to a single radiation dose d by n = αd + βd2. The
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number of lethal events among a population of cells (i.e. within a tumour) is proposed
to follow a Poisson distribution. The surviving fraction (SF ) of tumour cells within
a tumour after an applied dose d is then given by SF = e−(αd+βd
2). Parameters α
and β are determined empirically through fitting the SF equation to cell-survival
curves obtained through irradiating in-vitro tumour cell cultures with different doses
of radiation followed by counting the surviving fraction of cells after each irradiation.
After administering N fractions of radiation, each with dose d, the surviving frac-
tion of tumour cells is given by SF = e−N(αd+βd
2). Noting that the total prescription
dose is given by D = Nd, this equation can be re-expressed as SF = e−αD(1+
d
α/β ).
Let D1, d1, and SF1 represent the prescribed dose, dose/fraction, and the SF after
dose D1 is administered to the tumour respectively. The 2 Gy/fraction equivalent or
iso-effective dose (D2) can then be obtained by equating SF1 to SF2 where SF2 is the
theoretical SF after administering an equivalent prescription dose D2 to the tumour
in 2 Gy fractions (d2 = 2 Gy).
D2 =
(
d1 + α/β
d2 + α/β
)
D1 (2.1)
Currently, there is no strong consensus on the LQM parameter α/β for liver tumours
with published values ranging from 3.1 Gy to 15 Gy [21]. Consequently, a typical
tumour value of α/β = 10 Gy was used for this conversion. A sensitivity analysis
was also performed to assess the impact of using other α/β values on dose-response
parameters. A uniform dose distribution within the target was assumed owing to the
dose uniformity constraints described in §2.2.2.
To facilitate comparisons with Chang et al. [11], we elected to use the same logistic
TCP model [22] to fit the 6-month tumour control data:
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TCP =
1
1 + (D50/D)k
(2.2)
where D50 is the dose that would result in a 50% probability of local control, D is the
prescription dose and k controls the slope of the TCP curve. Similar to other response
studies [23, 24], the model was fitted to the data using the maximum likelihood
method, which can provide both the fitted parameters and the estimates of their
standard deviations [25].
In our context, the maximum likelihood method determines the values of D50 and
k, which maximise the probability of predicting response within our patient groups
using the TCP from equation 2.2. We employed a binary relationship where patients
either respond or do not respond to treatment, which we denote for the i-th patient
by Ri = 1 or Ri = 0, respectively. Here, response corresponds to observing local
control approximately 6 months (±1 month) post RT. The probability that patient i
responds or does not respond given a prescribed dose Di is given by
f(Di, Ri) = p
Ri
i (1− pi)1−Ri (2.3)
where pi is equal to the TCP defined by equation 2.2, evaluated at D = Di. A con-
strained minimisation procedure from the MATLAB optimisation toolkit (fmincon)
(The Mathworks, Inc., Natick, MA) was used to search for the values of D50 and k,
which minimise the negative of the log-likelihood function
l =
N∑
i=1
log[f(Di, Ri)] (2.4)
where N is the number of patients in the patient group of interest and f(Di, Ri) is
defined by equation 2.3.
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2.2.4 Local control definition
Tumour response was evaluated in the largest treated lesion in each patient. Local
control was defined using radiographic or tumour biomarker information depending
on data availability. Using radiographic information, local control corresponded to ob-
serving at least stable disease criteria or better using the Response Evaluation Criteria
in Solid Tumours v. 1.1 [26]. Tumour diameter measurements used to evaluate RE-
CIST criteria were obtained from radiologist reports. Using biomarker information,
local control corresponded to observing a ≤20% increase from baseline measurements
of AFP for HCC patients and CEA for MET patients.
AFP has recently been shown to be a reliable biomarker of radiological response
after locoregional therapy for HCC [27, 28]. CEA has also previously been used as a
biomarker for response and metastasis after surgical resection and chemotherapy for
colorectal carcinoma [29, 30]. Biomarker levels were required to exceed the normal
values either prior to or after RT in order for them to be included in the definition of
local control. The normal values used for AFP and CEA levels were 6 ng ml−1 and
5 ng ml−1, respectively [31, 32]. If a treated lesion met the criteria for radiographic
local control but not biomarker local control (or vice versa), then the lesion was still
considered to be locally controlled. If a patient did not have follow-up CT data, then
local control was assessed using biomarker data and vice versa. Data were censored
starting at the time of the last follow-up if a patient was lost to follow-up prior to
the loss of local control.
2.2.5 Local control analysis
Local control follow-up data were visualised using what we have termed dose-control
history plots. These plots contain horizontal timelines for each patient, which indicate
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follow-up history and outcomes. The timelines are displayed in order of increasing
prescription dose. Standard Kaplan-Meier analyses and log-rank tests were also per-
formed using SPSS Statistics v. 19 (IBM Corporation, Armonk, NY) to quantitatively
assess local control as a function of time.
Potential factors affecting local control, such as the radiation dose and pre-treatment
tumour volume, were explored using plots of patient pre-treatment tumour volume
vs the prescribed equivalent dose, with colour coding indicating time to loss of local
control or time to censor (last follow-up before loss of patient contact). Two-tailed
Spearman rank tests were used to test for possible correlations. Censored data (pa-
tients lost to follow-up before loss of local control) were included in correlative anal-
yses, provided the data were censored at least 6 months post RT. We expect that RT
had an effect if the tumour was controlled for at least 6 months, and, therefore, that
time to last follow-up for censored data may be correlated with the radiation dose or
pre-treatment tumour volume.
2.3 Results
Patient and treatment characteristics for the full HCC and MET groups included in
the local control analysis are summarised in table 2.1. The median follow-up time
was 197 days (27-1095 days) and 178 days (51-1101 days) for the HCC and MET
groups, respectively.
Sufficient follow-up data were available to assess 6-month local control for 27/36
(75%) HCC and 19/26 (73%) MET cases. 5/27 HCC and 1/19 MET patients died
prior to true observation of loss of local control. However, in all six cases, patient
charts indicated that there was no extrahepatic progression and that liver disease
progression was the cause of death. Therefore, these tumours were considered to be
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Table 2.1: Patient characteristics and treatment data. All summary statistics are me-
dians with ranges displayed in brackets. p-values were calculated using the Wilcoxon
rank sum test. Abbreviations : 3D-CRT, three-dimensional radiotherapy; CTV, clin-
ical target volume; HCC, hepatocellular carcinoma; IMRT, intensity-modulated ra-
diotherapy; MET, metastatic colorectal liver tumours; RFA, radiofrequency ablation;
TACE, transarterial chemoembolisation.
Characteristics HCC (n = 36) MET (n = 26) p-value
Age (years) 74 (22-87) 68 (42-90) 0.06
Gender
Male (%) 29 (81) 16 (62)
Female (%) 7 (19) 10 (38)
Child-Pugh score
Class A (%) 27 (75) 21 (81)
Class B (%) 8 (22) 5 (19)
Class C (%) 1 (3) 0
Previous treatment
Surgical resection (%) 0 8 (31)
Chemotherapy (%) 5 (14) 23 (88)
TACE (%) 9 (25) 0
RFA (%) 1 (3) 1 (4)
Number of liver lesions 1 (1-4) 2 (1-5)
Active extrahepatic disease (%) 11 (31) 12 (46)
Tumour diameter (%) 6.6 (3.0-18.0) 5.0 (1.0-13.0) 0.03
CTV (ml) 186 (8-995) 57 (5-1804) 0.02
Radiotherapy technique
3D-CRT (%) 25 (70) 21 (81)
IMRT (%) 8 (22) 4 (15)
Tomotherapy (%) 3 (8) 1 (4)
Gating (%) 21 (58) 15 (58)
Number of fractions 15 (6-20) 15 (6-21) 0.37
Dose per fraction (Gy) 4.0 (2.0-10.0) 3.6 (2.0-13.0) 0.24
Total dose (Gy) 52 (29-83) 55 (30-80) 0.78
Equivalent dose (Gy) 63 (33-107) 61 (33-154) 0.88
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uncontrolled at 6 months. 16/27 (59%) and 7/19 (32%) patients were locally con-
trolled at approximately 6 months post RT in the HCC and MET groups, respectively.
The logistic TCP model was fitted independently to the response data for each
subgroup using the end point of 6 months of local control (Figure 2.1). One outlier
within the HCC group was omitted prior to model fitting (107 Gy, uncontrolled at 6
months) owing to its severe contradiction with the trends indicated by the other data.
For reference purposes, the observed patient response data used by the maximum
likelihood fitting method are also indicated in Figure 2.1 as a function of equivalent
dose. These data were then binned and averaged to generate estimates of the observed
TCP at various dose levels and to assist in evaluating the quality of the model fits.
Horizontal whiskers indicate the range of doses included in each bin.
D50 was determined to be 53 Gy (σ = 5.6 Gy, 95% CI = 51-55 Gy) and 70 Gy
(σ = 6.6 Gy, 95% CI = 67-73 Gy), and the slope parameter k was estimated to
be 4.8 (σ = 2.0, 95% CI = 1.2-2.8) and 7.1 (σ = 3.3, 95% CI = 5.6-8.6) for the
HCC and MET groups, respectively. 2 Gy per fraction equivalent doses of 84 Gy
and 95 Gy are predicted to result in 90% 6-month local control rates for patients
with HCC and MET colorectal liver tumour, respectively. Uncertainty in the dose-
response curves was illustrated in Figure 2.1 by plotting the TCP model using the
fitted D50 parameters plus or minus two standard deviations while keeping the fitted
k parameter constant. The standard deviations of the parameter estimates serve as
surrogates for assessing the quality of the model fits, with higher values indicating
greater parameter uncertainty.
General treatment-related toxicities (e.g. nausea, abdominal pain, fatigue) were
scored using the Common Terminology Criteria for Adverse Events v. 3.0 (National
Cancer Institute, Bethesda, MD) for the subset of patients included in TCP analysis.
We note that both HCC and MET patient groups were retrospectively determined
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Figure 2.1: Tumour control probability curves and patient response data for the (a)
hepatocellular carcinoma and (b) metastatic colorectal liver tumours patient groups
approximately 6 months post treatment. The uncertainty estimates indicate the TCP
model plotted using the fitted D50 parameters plus or minus two standard deviations
while keeping the fitted k parameters constant.
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within this study. For the HCC group after 6 months, there were 5 asymptomatic
patients, 9 patients with Grade 1, 10 patients with Grade 2 and 2 patients with Grade
3 complications. For the MET group after 6 months, there were five asymptomatic
patients, three patients with Grade 1, eight patients with Grade 2 and three patients
with Grade 3 complications. Liver specific toxicities were scored using the same RILD
end point as the NTCP model used during planning [19]. No instances of Grade 3
or higher Radiation Therapy Oncology Group RILD were observed among any of the
HCC or MET patients.
Figure 2.2 summarizes the local control data acquired for the two patient groups
using dose-control history plots. The plots indicate all the radiographic and biomarker
local control data that were available for each HCC and MET patient. Between
the full HCC (n = 36) and MET (n = 26) cohorts, local control was determined
by radiographic data for 21/36 (58%) HCC and 13/26 (50%) MET patients at the
time of last follow-up, with local control determined by the AFP and CEA data for
the remaining patients. For HCC, only 12/36 patients had both radiographic and
biomarker data at the time of last follow-up and both measures were in agreement for
7/12 patients. For MET, only 5/26 patients had both radiographic and biomarker
data at the time of last follow-up and both measures were in agreement for 4/5
patients. The median follow-up time was 197 days (range, 27-1095 days) and 178
days (range, 51-1101 days) for the HCC and MET groups, respectively. At the time
of last follow-up, 21/36 (58%) HCC and 14/26 (54%) MET patients had lost local
control.
Kaplan-Meier analysis was performed on the local control data for the full HCC
(n = 36) and MET (n = 26) cohorts (Figure 2.3). The HCC and MET curves were
found to be significantly different (log-rank p = 0.03). For the HCC group, actuarial
1- and 2-year local control rates were 65% (45-85%) and 48% (23-73%), respectively.
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Figure 2.2: Dose-control histories for the (a) hepatocellular carcinoma and (b)
metastatic colorectal liver tumours patient groups. Horizontal lines correspond to
individual patient histories and are displayed in the increasing order of the radiation
treatment dose. Solid and dotted lines are alternated to facilitate visualization of
adjacent histories.
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Figure 2.3: Local control Kaplan-Meier curves for the (a) hepatocellular carcinoma
and (b) metastatic colorectal liver tumours patient groups (log-rank p = 0.03). CI,
confidence interval.
For the MET group, actuarial 1- and 2- year local control rates were 32% (6-58%) and
0% (0-42%), respectively. The median time to failure (loss of local control) between
HCC and MET groups was estimated to be 543 days [95% confidence interval (CI)
374-711] and 183 days (95% CI 72-294), respectively. To visualise how the data
are distributed about the D50 parameters, plots of pre-treatment tumour volume vs
equivalent prescribed dose with time to failure/censor colour coding were generated
(Figure 2.4). Data point radii were also related to time to failure/censor for improved
visualisation.
We performed two-tailed Spearman’s rank correlation tests on the subset of data
included in Figure 2.4c (n = 27/36) and 2.4d (n = 19/26). Dose was significantly
correlated with tumour volume for both the HCC (ρ = −0.73, p ≤ 0.001) and the
MET groups (ρ = −0.62, p = 0.005). However, baseline tumour volume was not sig-
nificantly correlated with time to failure/censor for either of the HCC (ρ = −0.047,
p = 0.82) or of the MET groups (ρ = −0.44, p = 0.06). Dose and time to fail-
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ure/censor were significantly correlated for the MET group (ρ = 0.50, p = 0.03) but
not for the HCC group (ρ = 0.22, p = 0.26).
Figure 2.4: Pre-treatment clinical target volume (CTV) vs the prescribed equivalent
dose with time to loss of local control/censor colour coding. (a) and (b) Plots for
the hepatocellular carcinoma and metastatic colorectal liver tumours patient groups,
respectively. (c) and (d) contain the same information except we have omitted the
data censored prior to 6 months. Outliers (35 Gy, 1804 ml, 0.3 years), (33 Gy, 1122
ml, 0.14 years) and (154 Gy, 7 ml, 0.14 years) have been omitted from (b) to better
visualise trends. D50 is indicated by the dashed vertical line.
56
2.4 Discussion
In this study, we have demonstrated 6-month dose-response relationships for patients
treated with RT for HCC or MET colorectal liver tumour groups. The heterogeneous
doses prescribed to the patients within the HCC and MET groups provided a valuable
opportunity to evaluate dose response in the liver. Although dose-response relation-
ships have previously been established for HCC [13] and MET [11] patients, currently,
there is a lack of literature on dose response and explicit TCP modelling for the liver.
These data are critical if personalised radiobiologically guided dose escalated RT is
to be applied to patients. This study employed the maximum likelihood method to
fit a TCP model to HCC and MET tumour response data, adding to this body of
literature. To our knowledge, this is the first study to explicitly model TCP for HCC
patients and the second to do so for MET patients [11].
Park et al. [13] reported a 77% partial response rate, 4-6 weeks post RT, among a
subset of patients with HCC (n = 83) who were prescribed a radiation dose ≥50 Gy.
In the present study, we found that a 50% response rate at 6 months post RT could
be achievable with a higher dose of 53 Gy ( σ = 5.6 Gy). This suggests that dose
escalation may improve the durability (duration of local control) of tumour response
which is consistent with the findings of Park et al. [13].
Chang et al. [11] reported a D50 value of 68 Gy (standard error = 6 Gy) with
an end point of 12 months of local control among patients (n = 65) treated with
SBRT for MET colorectal liver tumours in a multicentre pooled analysis. Here, we
found a slightly higher D50 value of 70 Gy (standard error = 1.5 Gy) for an end
point of 6 months of local control among a similar group of patients, although this
difference is within the uncertainties of the two D50 estimates. If we had similar
patient demographics, we would expect that higher doses should translate to improved
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local tumour response durability. Therefore, a 12-month response D50 value as in
Chang et al. [11] would be expected to be higher than a 6-month response value.
However, an important difference between the patient population in Chang et al. [11]
and the MET group is the median tumour volume, which is smaller in Chang et al.
[11] than in the present study [30 cc, range = (0.5, 3008) vs 57 cc, range = (5, 1804)].
A steeper dose-response relationship was found in our study with a slope parameter
of 7.1 (standard error = 0.8) compared with 4.2 (standard error = 1.6) as reported
by Chang et al although this difference is within the uncertainties of the two slope
parameter estimates.
Prior to TCP modelling, the LQM was used to convert doses to 2 Gy per fraction
equivalents. The LQM has been shown to overestimate cell kill for dose fractionations
beyond 8-10 Gy per fraction [33]. Although some patients within this study received
higher ablative doses, 96% of the HCC patients and 95% of the MET patients included
in the TCP analyses received ≤8 Gy per fraction, supporting our use of the LQM.
None of the included patients received doses exceeding 10 Gy per fraction.
Currently, there is no strong consensus on α/β ratios for HCC, and, to our knowl-
edge, there are no published data on ratios for MET colorectal liver tumours. Con-
sequently, a single α/β ratio of 10 Gy was used to determine the 2 Gy per fraction
equivalent doses for both the HCC and the MET groups prior to dose-response mod-
elling. Therefore, we investigated the sensitivity of our D50 and k dose-response
parameter values to the α/β ratio. Wigg et al. [21] have compiled a short list of
reported HCC α/β ratios. We used these alternative values to recompute the 2 Gy
per fraction equivalent doses and then recalculate the dose-response parameter values
(Table 2.2). The parameter variability for values of α/β ≥ 7.2 Gy was much smaller
than the uncertainty (standard deviation) in the parameter estimation itself. There-
fore, our reported values should be robust to current α/β uncertainty provided that
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Table 2.2: Influence of using different α/β ratios on estimated dose-response param-
eters. The prescription doses were converted to 2 Gy per fraction equivalent doses
using each α/β ratio followed by tumour control probability model fitting. Parame-
ter results for α/β = 10 Gy were included for comparison. Standard deviations are
shown in brackets. Abbreviations : D50, dose that would result in a 50% probability of
local control; k, slope parameter; HCC, hepatocellular carcinoma; MET, metastatic
colorectal liver tumours.
HCC MET
α/β (Gy) D50 (Gy) k D50 (Gy) k
3.1 63 (6.7) 4.8 (2.0) 80 (8.4) 6.1 (2.7)
7.2 55 (5.8) 4.9 (2.0) 72 (7.2) 6.8 (3.1)
10 53 (5.6) 4.8 (2.0) 70 (6.6) 7.1 (3.3)
15 51 (5.6) 4.6 (2.0) 67 (6.0) 7.4 (3.5)
liver tumours are early responding tissues.
In this study, our primary aim was to examine whether dose-response relation-
ships exist for HCC and MET patients. Since limited research has been done on
liver tumour dose response, we employed the commonly used logistic TCP model to
fit the observed data. This provided a simple way to demonstrate dose response in
the liver and facilitated comparison with the only other existing literature. In the
future, more refined TCP models will be investigated, which account for non uniform
tumour doses and tumour volumes. Furthermore, the predictive utility of the mod-
els will then be investigated in independent data sets. Toxicity among the patients
included in the TCP analyses was comparable to previous liver irradiation studies
[10, 11, 34–36]. The large tumour sizes in the HCC and MET patient groups may
have contributed to marginally higher toxicities. However, HCC patients who experi-
enced Grade 3 complications post RT had pre-existing Grade 2 complications before
treatment. Similarly, for the MET group, one patient with post-RT Grade 3 compli-
cations had pre-RT Grade 3 complications and the remaining two had pre-RT Grade
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1 complications. In addition, no instances of Grade 3 or higher Radiation Therapy
Oncology Group RILD were observed among either of the two groups.
We found that the dose and time to loss of local control/censor were correlated
for the MET patients but not for the HCC patients. This could be because of the
increased percentage of patients in the HCC group who were lost during follow-up
prior to observation of loss of local control (18/27, 67% for HCC vs 5/19, 26% for
MET). HCC patients tend to lose local control later than MET patients, and therefore
patients are more frequently lost to follow-up prior to observation of loss of local
control. Although data censored at later times may have a connection to treatment
parameters, inclusion of these data in the analysis may weaken correlations in the
HCC group since time to last followup (or censor) can be related to factors aside
from the dose. Tumour volume was not found to be correlated with time to loss of
local control/censor for both the HCC and MET groups, which is in agreement with
the studies by Andolino et al. [10] and Chang et al. [11], respectively. Therefore,
although the HCC tumours were significantly larger than the MET tumours (table
2.1), tumour size could not be used to explain the significant differences between
HCC and MET dose-response parameters or local control rates. Prescription dose
was also not significantly different between the two groups (table 2.1). In the future,
Cox regression analyses may provide a more robust understanding of the interactions
between tumour volume, dose, and time to loss of local control when compared to
the correlation tests performed within the present study.
A key difference between the two demographics was the heavily pre-treated nature
of the MET group. 88% of MET patients had received previous chemotherapy com-
pared with only 14% of HCC patients. This is consistent with the pattern of referral
at our institution, whereby MET patients are usually treated with RT after failing
multiple chemotherapy regimens. Consequently, the MET patients tend to be further
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along in their disease than the HCC patients. This may explain why the median time
to loss of local control for the MET group (183 days) was much lower than for the
HCC group (543 days) as well as why higher doses were required to control MET
colorectal liver tumours.
The local control rates determined for the HCC and MET patients in this in-
vestigation may seem low when compared with the current literature. For example,
Andolino et al. [10] found that HCC patients (n = 37) who were ineligible for trans-
plant had a 2-year local control rate of 87% compared with the 48% (23-73%) rate
observed in this study. Similarly for the MET group, Chang et al. [11] reported 1-
and 2-year local control rates of 67% and 55%, respectively, for patients with MET
colorectal liver tumours (n = 65) compared with the 32% (6-58%) and 0% (0-42%)
local control rates reported here. Currently, there is a lack of consensus on whether
liver tumour size correlates with radiotherapy outcome [10, 11, 35, 36]. However,
a notable difference between the present and aforementioned studies is tumour size,
which will be summarised in the subsequent paragraph. The lower local control rates
observed in this study is the reason for our choice of a 6-month local control TCP end
point (instead of 1 year), particularly among the MET patient group whose median
time to loss of local control was approximately 6 months. This ensures that patient
response within the two groups can be maximally stratified as a function of dose.
For Andolino et al. [10], the median tumour diameter was 3.5 cm [range = (1,
6.5)] compared with 6.6 cm [range = (3, 18)] for our HCC group. In contrast, Tse et
al. [34] investigated a group of HCC and intrahepatic cholangiocarcinoma patients
(n = 49) with more comparable tumour sizes and reported a 65% 1-year local control
rate that is similar to the 1-year local control rate reported here. The median tumour
volume in their investigation was 173 cc [range = (9, 1913)] compared with 186 cc
[range = (8, 995)] for our HCC group. For Chang et al. [11], the median tumour
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volume was 30 cc [range = (0.5, 3008)] compared with 57 cc [range = (5, 1804)] for
the MET group in this study.
In this study, we used a combination of biomarker and radiographic response data
to help define local control. However, for MET patients with untreated metastatic
tumour burden, multiple tumours could be contributing to increased CEA levels that
hide decreases caused by treatment of the target lesion. We attempted to mitigate
this effect by allowing for a <20% increase in biomarker levels within the local control
definition and by supplementing biomarker data with local radiographic information.
2.5 Conclusion
In conclusion, we have found radiation dose-response relationships for patients with
HCC and MET groups. D50 was determined to be 53 Gy (σ = 5.6 Gy) and 70 Gy
(σ = 6.6 Gy) and the slope parameter k was estimated to be 4.8 (σ = 2) and 7.1
(σ = 3.3) for the HCC and MET groups, respectively. 2 Gy per fraction equivalent
doses of 84 Gy and 95 Gy were predicted to result in 90% 6-month local control
rates for patients in the HCC and MET groups, respectively. RT for HCC and
MET results in significantly different local control rates at our institution, which may
warrant an investigation into the effect of earlier RT referral for patients with MET.
Improved understanding of the dose-response relationships for patients with primary
or metastatic liver cancer will help to inform future dose prescriptions.
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Chapter 3
An augmented parametric response map
with consideration of image registration
error: towards guidance of locally
adaptive radiotherapy ∗
3.1 Introduction
Traditionally, the aim of radiation therapy (RT) is to deliver a high uniform dose to
the tumour while limiting the dose received by surrounding normal tissues. However,
an increasing number of studies as reviewed by Dewhirst et al. [1] suggests that there
may be a large amount of variability in intra-tumoural radio sensitivity. Consequently
there has been a push towards developing new treatment strategies such as sub-volume
boosting or dose-painting by numbers to account for this variability [2].
Since the local radio-sensitivity within a tumour can also vary during the course of
treatment [1], these personalized strategies may require an adaptive implementation
∗This chapter has been previously published as Lausch et al. An augmented parametric response
map with consideration of image registration error: towards guidance of locally adaptive radiother-
apy. Phys. Med. Biol., 2014;59:7039-7058.
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[2]. Imaging-based biomarkers of local radio-sensitivity or tumour response could be
evaluated one or more times during the treatment course to ensure the continuing
optimality of the non-homogeneous dose distribution. In case of a sub-optimal dose
distribution, the RT plan could be updated to take advantage of each patient’s unique
tumour response to radiation.
A vital step towards personalized adaptive RT is the development of reliable
imaging-based biomarkers which can predict the early localized influence of radia-
tion on the tumour. Recently, Galban et al. [3] presented a promising method for
predicting treatment response known as the parametric response map (PRM). The
PRM is generated through a local voxel-wise analysis of repeat imaging with the ob-
jective of predicting a global measure of post-treatment response or progression. The
PRM also indicates which tumour voxels are associated with the predicted response or
progression. Since the analyzed images are typically acquired prior to and during the
treatment course, response could potentially be predicted on a voxel-wise basis during
the treatment itself. Therefore the PRM approach may be ideal for guiding adaptive
RT strategies prior to or in the absence of observable changes in tumour volume.
To date, the method’s predictive utility has been demonstrated for several different
pathologies and treatments such as RT for gliomas and head and neck cancers and
chemoembolization for hepatocellular carcinomas [3–8].
A major challenge towards guiding RT using voxel-based analyses such as the
PRM is their inherent sensitivity to image registration error (IRE) [9–11]. Repeat
imaging must be spatially registered to establish correspondences between voxels
prior to analysis. However, voxel-based comparisons may be sensitive to IRE with
the amount of sensitivity depending on the interplay between the magnitude and
direction of the error and the size, orientation and complexity of the image features.
Consequently, the sensitivity of voxel-based analyses to IRE is a property of the
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analyzed images and may be different for every patient. In a previous work we
demonstrated that indeed the local voxel-wise classification accuracy of the PRM
method may be prohibitively sensitive to small registration errors [12]. While the
overall PRM analysis may still be correlated with a global measure of response, IRE
can cause individual responding or progressing tumour voxels to be misclassified as
one another, which could lead to targeting errors if PRMs were used to guide RT.
Since the careful management of uncertainty is a critical component of the RT
workflow, robust voxel-based analysis methods are needed which permit the user to
identify whether IRE-related analysis uncertainty can influence target delineation.
Here our primary objective was to address this challenge by extending the original
single-threshold PRM method [3] to include a PRM analysis confidence interval re-
lated to the influence of IRE (§3.2.2, §3.2.3, §3.2.4). In addition, we incorporate
multiple graded classification thresholds into this framework in order to facilitate
visual assessment of IRE-related analysis uncertainty and regional tumour response
trends (§3.2.5). Risholm et al. [10] and Murphy et al. [11] have previously reported on
accounting for IRE uncertainty during RT dose accumulation; however to our knowl-
edge the present study is the first to explore IRE-related image analysis uncertainty
within the context of image-guided locally-adaptive RT.
The augmented PRM (A-PRM) method was demonstrated and contrasted with
the PRM through application to repeat functional imaging with simulated IRE (§3.3).
The new method was shown to help visualize and quantify the influence of registration
error on PRM analysis while also providing additional contextual information which
could be useful for guiding adaptive RT strategies such as sub-volume boosting (§3.4
and §3.5). Strategies for using the A-PRM method to guide RT in the presence of
IRE-related PRM analysis uncertainty are discussed.
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3.2 Methods
3.2.1 Original single-threshold parametric response map
PRMs are generated by analyzing the voxel-wise changes between spatially registered
baseline and follow-up imaging of some region of interest (e.g. tumour). Since func-
tional imaging is typically analyzed, registration is often performed by applying a
transformation derived from the registration of accompanying co-registered anatom-
ical images. The PRM indicates which voxels within the region of interest (ROI) are
significantly increasing, decreasing, or not significantly changing in function. This in-
formation has been shown to correlate with global treatment response and progression
for several datasets [3–8].
Let d(x) represent the observed voxel-wise change in function for a single voxel
at position x within the baseline image set. The functional change is classified as
significantly increasing or decreasing if d(x) > T or d(x) < −T respectively, where
T is a single constant threshold value. Voxels where |d(x)| ≤ T are classified as
not significantly changing. The threshold T is determined by the functional changes
occurring within an ROI of corresponding healthy tissue. For example, Galban et al.
[3] analyzed repeat functional imaging of gliomas and used an ROI on the contralateral
side of the brain that was homologous to the tumour ROI in a subset of patients.
Follow-up functional image voxel values within the healthy ROI are plotted versus
the corresponding voxel values within the baseline functional images. A line is then
fit to the plot and [−T, T ] corresponds to the 95% confidence interval in the residuals
from the linear fit. Henceforth we will refer to the PRM threshold as T95.
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3.2.2 Influence of image registration error on PRM analysis
Since the PRM threshold T95 is determined from a summative analysis of a large
population of voxels, it should be robust to the influence of several sources of uncer-
tainty such as IRE and image noise. More precisely, the calculated threshold value
for a patient would not be expected to vary significantly due to these uncertainties.
However, IRE introduces a second source of uncertainty into the PRM method. In
the presence of IRE, each voxel-wise intensity difference is also uncertain because it
is no longer clear which voxel intensity values should be compared to one another in
the registered images. In this context, an individual voxel intensity difference takes
on a distribution of possible values which could correspond to different classification
outcomes when each value is compared to the PRM threshold T95.
To illustrate this, we consider two 1D images, I1 and I2. Let D(x) represent the
distribution of possible voxel-wise differences for a single pixel at position x within the
baseline image, I1. Figure 3.1 provides a motivating example for determining D(x)
in the presence of IRE. When IRE = 0, the difference between I1 and I2 at position
x is given by a single value d(x) = I2(x) − I1(x). However when IRE is non-zero
it is no longer certain which pixel in I2 corresponds to I1(x). Therefore d(x) takes
on a distribution of potential values D(x) which is produced by taking the difference
between I1(x) and a neighborhood (Ω) of pixels around and including position x in I2.
Ω is defined by all the likely registration errors that could have occurred at position
x.
If T95 = 2 in figure 3.1, then the analyzed pixel would be classified by the PRM
method as either significantly decreasing or not significantly changing depending on
which single pixel intensity difference was actually observed from the distribution
D(x). Consequently, IRE could lead to pixel (or voxel) misclassification by the PRM
method.
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Figure 3.1: 1D example for determining the distribution of possible image differences
at a single image position x when there is non-zero image registration error (IRE). I1
and I2 are two 1D images and D(x) is the distribution of possible differences between
I1 and I2 at position x. In this example, the IRE has a potential value of two pixels
in either direction and spans the spatial domain Ω.
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3.2.3 Incorporating IRE uncertainty into PRM analysis
For clarity we return to the 1D example from figure 3.1 however in subsequent sections
the proposed methods are applied in 3D.
Instead of classifying a pixel based on a single intensity difference value observed
from the distribution D(x), the expected value of this distribution could be used.
Let {∆si(x)} represent the set of potential registration errors for a pixel at position
x where ∆si(x) is the distance between the position of the i -th pixel in Ω and the
position x. If p(x,∆si(x)) represents the probability that the IRE is ∆si(x) for
the pixel at position x and Di(x) is the resulting pixel intensity difference then the
expected value for D(x) is given by
D(x) = E[D(x)] =
∑
i
Di(x)p(x,∆si(x)) (3.1)
In practice, the probability distribution function (PDF) p for the registration error
is unknown and must be approximated. The estimation of p will be discussed in
the next section. The uncertainty in D(x) can then be represented by the standard
deviation,
σIRE =
√∑
i
(Di(x)−D(x))2p(x,∆si(x)) (3.2)
The expected value of the PRM analysis can be obtained for each pixel by compar-
ing D(x) to the PRM threshold T95. Upper and lower bounds of a PRM analysis
confidence interval (CI) can then be generated by comparing |D(x)|+ aσIRE(x) and
|D(x)| − aσIRE(x) to T95 respectively where a is a positive constant that controls
the width of the computed confidence interval (e.g. a = 2 implies a 95% CI). If
|D(x)| − aσIRE(x) < 0 then the voxel is classified by ||D(x)| − aσIRE(x)| and the
direction of the change (i.e. increasing or decreasing) is reversed.
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3.2.4 Estimating the IRE probability distribution function
Accurate voxel-wise estimation of p poses an extremely challenging task and is an
open area of research [9, 11, 13–16]. As a first step, and for demonstration purposes,
we explore the utility of a simple Gaussian definition of p which is defined by a single
conservative estimate of the voxel-wise IRE in each coordinate direction within the
ROI. This approach was also adopted as it mirrors uncertainty management in other
aspects of the RT workflow such as the use of standardized margins for generating
planning target volumes. However in the future it would be straightforward to extend
this method to spatially varying uncertainties if more localized IRE information were
available.
Let [IRELR, IREAP , IRESI ] represent the upper bound of a prediction interval
for the spatial misalignment due to IRE within the ROI in the left-right, anterior-
poster and superior-inferior directions respectively. We defined p by a 3D spatially
invariant ellipsoidal Gaussian distribution where the standard deviation along each
axis is given by,
[3σLR, 3σAP , 3σSI ] = [IRELR, IREAP , IRESI ] (3.3)
In practice, this upper bound would need to be estimated and provided by the user.
Accordingly, the impact of under and over-estimation of the IRE is also reported in
this study.
3.2.5 Augmented parametric response map
The A-PRM combines the ideas presented in §3.2.3 and §3.2.4 with the use of multiple
graded classification thresholds [17] in order to enhance visualization of IRE-related
analysis uncertainty and regional tumour response trends. Every voxel in the A-
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PRM is classified by a specific threshold that indicates the magnitude and sign of
the functional change. In contrast to the original single threshold PRM, the A-PRM
permits visualization of the full distribution of tumour functional changes instead
of only those changes with magnitudes that exceed the T95 threshold. This should
facilitate identification of responding or progressing tumour sub-volumes that could be
targets for adaptive RT and permit visualization of IRE-related analysis uncertainty
throughout the ROI when combined with the calculation of the analysis confidence
interval.
Let {Ti} for i = 1 . . . 95 represent a set of classification thresholds which corre-
spond to the 1%-95% confidence intervals for the linear fit residuals used to determine
the original PRM threshold where a normal distribution is assumed for the linear
fit residuals. Accordingly, T95 represents the threshold used by the original PRM
method. The expected value of each voxel-wise change D(x) is uniquely classified
by the maximum Ti for which |D(x)| ≥ Ti. The A-PRM then corresponds to an
image of the ROI where each voxel value is given by +i or −i depending on whether
the change was an increase or a decrease respectively. Therefore each A-PRM voxel
value indicates the maximum threshold exceeded by the expected magnitude of each
voxel-wise functional change as well as the direction of the change. This calculation
is repeated for each voxel within the region of interest.
As a first step and for demonstration purposes, the associated confidence interval
was chosen to span ±3σIRE. Other confidence intervals were also investigated and
are reported within this study in a sensitivity analysis. To generate the upper bound
of the confidence interval, a voxel is classified by the maximum Ti for which |D(x)|+
3σIRE(x) ≥ Ti. To generate the lower bound of the confidence interval, a voxel is
classified by the maximum Ti for which |D(x)| − 3σIRE(x) ≥ Ti. Response maps
corresponding to these upper and lower bound classifications were also generated and
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are denoted by A-PRM+ and A-PRM− respectively. If |D(x)| − 3σIRE(x) < 0 then
the voxel is classified according to the magnitude of the left hand side of the inequality
and the direction of the change (i.e. increasing or decreasing) is reversed.
Figure 3.2 provides an illustrative example which contrasts the PRM and A-
PRM voxel classification approaches using scatter plots. Without loss of generality,
all analyses occur in the spatial frame of reference of the baseline image set (i.e.
uncertainty is in follow-up image voxel values).
Figure 3.2: Voxel-wise change classification using the PRM and A-PRM methods
for eight example voxels (A-H). The observed and expected change for each voxel
are marked with an x and a circle, respectively, and the error bars span ±3σIRE.
The table indicates the threshold that would be used to classify voxels A-H for each
method with the sign indicating whether the change was an increase or a decrease.
The range reported for the A-PRM represents classification uncertainty due to IRE
(i.e. the confidence interval). A-PRM+, the upper bound of the interval, classifies
voxels by the ends of the error bars furthest away from the unity line in the plot.
Conversely, A-PRM−, the lower bound of the interval, classifies voxels by the ends of
the error bars closest to the unity line.
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3.3 Evaluation
Ideally, the A-PRM method would be evaluated using perfectly registered pairs of
functional images. PRM and A-PRM analysis of these images would be uncontami-
nated by IRE and would serve as a “ground truth” analysis. Controlled amounts of
IRE could then be simulated by spatially perturbing the registered images. The PRM
and A-PRM analyses would be repeated and the voxel classification results could be
compared to the ground truth analyses to determine the relative performance of the
two methods in the presence of known IRE.
However in practice the transformation required to perfectly register an image pair
is unknown. For the purposes of this study, we approximate this transformation with
the transformation output from a non-rigid registration of the functional image pairs.
Due to residual IRE, the functional changes conveyed by the resulting “ground truth”
PRM and A-PRM analyses may not fully coincide with the true functional changes
occurring within the tumours. However, this should serve as a suitable approxima-
tion for demonstrating and verifying the behavior of the A-PRM methodology. The
evaluation pipeline is summarized below and detailed further in subsequent sections.
(a) non-rigidly register original baseline and follow-up functional images
(b) perform PRM and A-PRM analysis on non-rigidly registered images to produce
ground truth analysis
(c) apply known rigid transformations to non-rigidly registered images to simulate
controlled rigid IRE
(d) perform PRM and A-PRM analysis on images with simulated rigid IRE and
compare to ground-truth analysis
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3.3.1 Image data
CT-perfusion scans of four patients with high-grade glioma and four patients with
hepatocellular carcinoma (HCC) were used to demonstrate the A-PRM methodology.
Pre and post-RT scans were acquired using a 64 slice scanner (Discovery VCT or
CT750HD, GE Healthcare, Waukesha, WI). Glioma scans were acquired with a voxel
size of 0.5 mm by 0.5 mm by 5 mm and a temporal sampling of 1 s for the first 45 s
and 15 s for the remaining 105 s. HCC scans were acquired with a voxel size of 0.7
mm by 0.7 mm by 5 mm and a temporal sampling of 2.8 s. Glioma and HCC image
volumes consisted of 512 by 512 by 8 voxels and 512 by 512 by 16 voxels respectively.
The specific imaging protocols and perfusion analysis methods used for the glioma
and HCC groups are further described in Yeung et al. [18] and Jensen et al. [19]
respectively.
Blood volume (BV) and arterial blood flow maps (ABF) from the CT-perfusion
analyses were the functional images analyzed for the glioma and HCC cases respec-
tively (figure 3.3). BV maps were investigated for the glioma cases since MRI derived
relative BV has previously been shown to have predictive utility for brain tumours
using the PRM method [3]. ABF maps were investigated for the HCC cases since
arterial phase enhancement in contrast-enhanced CT scans may have the potential
to identify viable liver tumour using the PRM method [8]. These functional data are
sufficient for evaluating the A-PRM methodology and are promising candidates for
response analysis; however, verifying their predictive utility is outside the scope of
the present study.
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Figure 3.3: Example slices from the functional image data used for all simulations.
(a) Pre and post-RT blood volume maps for four different gliomas. (b) Pre and post-
RT arterial blood flow maps for four different hepatocellular carcinomas. tumour
functional maps were non-rigidly registered and superimposed on the pre-RT aver-
age dynamic contrast-enhanced computed tomography (DCE-CT) images for each
patient.
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3.3.2 Image registration
The Flexible Algorithms for Image Registration (FAIR) toolkit was used to non-
rigidly register the functional images [20]. Pre and post-RT functional images were
registered by applying a transformation derived from non-rigidly registering accom-
panying co-registered anatomical CT images. Registration was performed using a
multi-resolution elastic registration algorithm based on normalized gradient fields
(NGF). The NGF edge parameter was set to 5. The linear elastic Lame parameters µ
and λ were set to 1 and 0 respectively and the regularization weighting parameter was
set to 500. The maximum deformation grid considered by the multi resolution frame-
work consisted of 256 by 256 by 32 control points. Effective registration parameter
values were determined through trial and error.
3.3.3 Simulating image registration error
Each set of registered follow-up functional images was spatially perturbed by 1000
randomly selected rigid transformations. Translations and rotations were sampled
from normal distributions with zero means and 1 mm and 1◦ standard deviations
respectively which produced a spectrum of IREs within previously reported ranges
for brain and liver [21, 22]. The centre of rotation was defined to be the centre of each
image volume. The spatial locations of all voxels within the functional images were
known before and after each simulation permitting exact calculation of the simulated
IRE throughout the investigated ROIs.
3.3.4 Response maps
PRMs and A-PRMs were first generated for each patient from the non-rigidly regis-
tered functional image data without simulated IRE. Patient-specific sets of thresholds
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{Ti} for i = 1 . . . 95 were determined from normal tissue ROIs defined for each pa-
tient. For the HCC cases, this ROI was defined for each patient as the entirety of
the non-tumour bearing liver. For glioma cases, normal tissue ROIs were defined as
tumour-homologous regions on the contralateral side of the brain with respect to the
tumour.
A thousand different PRMs and A-PRMs were then generated for each patient
corresponding to analysis of the registered functional images that contained a thou-
sand different magnitudes of simulated rigid IRE. For each IRE simulation, the 99th
percentile of the known tumour voxel displacements in each coordinate direction was
used to define [IRELR, IREAP , IRESI ] and the IRE PDF p defined in §3.2.4. This
definition should ensure that the width of the gaussian IRE probability distribution
function p encompasses the full range of simulated IREs. The sensitivity of the A-
PRM method to different IRE estimates is also reported.
3.3.5 Analysis
Voxel classification outcomes from the PRM and A-PRM analyses with simulated
IRE were compared to the PRM analyses without simulated IRE for each patient.
Therefore the ground-truth analyses within this study were defined by the PRMs
generated from the non-rigidly registered image data prior to IRE simulation. Three
different investigations were performed.
3.3.5.1 Voxel classification performance
First, the true classification rates for the PRM and A-PRM methods were plotted
as a function of median tumour voxel IRE for each patient. Analysis was performed
with respect to the original T95 threshold and separate plots were generated for the
decreasing, no change, and increasing classes. The true classification rate represents
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the fraction of the total voxels that belong to a given class that are correctly identified
as such by the classification method. The purpose of this analysis was to compare
how well the ground truth PRM information is preserved in the PRMs and A-PRMs
when both are influenced by IRE. This analysis was also performed on the maps
corresponding to the bounds of the A-PRM confidence interval (A-PRM− and A-
PRM+).
True classification rates were also computed for the original PRM method after
performing a spatial expansion of the regions identified as significantly increasing and
decreasing within the IRE-contaminated PRMs. The purpose of this additional anal-
ysis was to identify if the simple spatial margin approach used to manage patient
position uncertainty in RT dose planning can be used to manage IRE uncertainty
in PRM analysis. Regions classified as increasing and decreasing were expanded by
[IRELR, IREAP , IRESI ] in each coordinate direction. If regions classified as increas-
ing and decreasing overlapped with each other after expansion, then the overlap-
ping region was classified as no-change. Spatially expanded PRMs were denoted by
PRMexp.
3.3.5.2 Sensitivity to IRE estimation
Second, we assessed the impact of under or over-estimation of [IRELR, IREAP , IRESI ]
on the A-PRM method. Outside of a simulation context this information is unknown
and would need to be estimated to define the IRE PDF p. Therefore for all IRE
simulations, another set of A-PRM analyses were performed for each patient corre-
sponding to six different estimations of [IRELR, IREAP , IRESI ]. Each IRE estimate
was defined by increasing or decreasing the known 99th percentile of the tumour voxel
displacements in each coordinate direction by 1 mm, 3 mm, and 5 mm. If decreas-
ing the known 99th percentile of the voxel displacements along a coordinate direction
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resulted in a negative IRE, then the IRE estimate was set to zero along that direction.
Voxel classification accuracy with respect to the T95 threshold was re-computed
in each case to investigate A-PRM sensitivity to the IRE estimate.
3.3.5.3 Generalized A-PRM analysis
Third, an analysis was performed on a generalized version of the A-PRM method
corresponding to classification based on the inequality |D(x)| + aσIRE(x) ≥ Ti. The
constant a was varied from −6 to 6 to produce a spectrum of different A-PRMs for
each magnitude of simulated IRE. Accordingly, maps generated using a = −3, a = 0,
and a = 3 correspond to the originally proposed A-PRM−, A-PRM, and A-PRM+
maps respectively.
3.4 Results
Figure 3.4 depicts representative slices from the 3D PRM and A-PRM analyses of
the non-rigidly registered functional images from figure 3 prior to IRE simulation.
Therefore, figure 3.4 PRMs (first rows) represent slices from the ground truth analyses
used throughout this study. Figure 3.4 A-PRMs (second rows) were generated with
IRE set to 0 since we used the non-rigidly registered functional images as a zero-IRE
reference within this study. Consequently, there is no IRE-related analysis uncertainty
and the A-PRM confidence interval is not displayed as it has zero width. Since IRE is
set to zero, the figure 3.4 A-PRMs solely demonstrate the impact of adding multiple
graded thresholds to the original PRM method as in Lausch et al. [17].
Figure 3.4 A-PRMs contain all of the same information as the PRMs but also pro-
vide additional contextual information by using multiple graded thresholds to classify
the entire distribution of functional changes within the tumour. For example, distinct
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Figure 3.4: PRM (first row) and A-PRM (second row) analyses of the functional
image data from figure 3.3(a) (gliomas) and 3.3(b) (HCCs), respectively, with IRE =
0. Response maps have been superimposed on the corresponding pre-RT average
DCE-CT images for each patient. Notable sub-volumes of functional increase are
highlighted for Glioma-3 and HCC-3 (dashed ellipses).
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sub-volumes of functional increase and decrease became more clearly observable in
the A-PRMs with notable examples indicated by dashed ellipses in the Glioma-3 and
HCC-3 A-PRMs.
For figure 3.4, there was no IRE-related analysis uncertainty. In contrast, figure
3.5 demonstrates how the figure 3.4 analyses for glioma-1 and HCC-3 would change
if 3 mm of isotropic IRE was assumed after non-rigid registration. Maps produced
from the original PRM method (§3.2.1) and the A-PRM method which incorporates
both IRE uncertainty and graded thresholds into the PRM (§3.2.5) are shown for
comparison. Since the original PRM method does not take IRE into consideration,
the two original PRMs shown in figure 3.5 are the same as those shown in figure
3.4. Uncertainty analysis can also be incorporated into the original PRM method as
discussed in section §3.2.3. PRMs which incorporate IRE uncertainty (but without
graded thresholds) are also shown in 3.5 for further comparison. To facilitate visual-
ization of differences between the upper and lower bounds and the the expected value
map, magnitude difference images were also included in figure 3.5. These images were
generated by subtracting the magnitude of the expected value maps from the upper
and lower bound maps.
The figure 3.5 A-PRMs contain all of the same information as the figure 3.5 PRMs
that incorporate IRE uncertainty but also classify the functional changes occurring
in the rest of the ROI using multiple graded thresholds. The non-zero IRE produces
a non-zero confidence interval reflecting potential IRE-related analysis uncertainty.
For the A-PRM method, the lower bound estimate (A-PRM−) classifies voxel-wise
changes with lower magnitude thresholds while the upper bound estimate (A-PRM+)
classifies voxel-wise changes with higher magnitude thresholds. This can be observed
in the magnitude difference images. The upper and lower bounds maps correspond
to the bounds of the analysis confidence interval. For the A-PRM, these bounds cor-
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Figure 3.5: Example parametric response maps (PRMs) and augmented PRMs when
the uncertainty due to 3 mm of isotropic IRE is incorporated into the PRM and
A-PRM analysis of (a) glioma-1 and (b) HCC-3 from figure 3.4.
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respond to A-PRM+ and A-PRM− respectively. The magnitude difference images in
figure 3.5 also provide a representation of the width of the confidence interval for each
voxel in the A-PRM analysis. Regions of high IRE-related analysis uncertainty are
reflected by non-zero values in the magnitude difference images. High uncertainty re-
gions appeared in the vicinity of A-PRM feature boundaries like the interface between
the decreasing (blue) and increasing (red) rims in figure 3.5(a).
3.4.1 Voxel classification performance
The PRM and A-PRM true classification rates with respect to the T95 threshold were
plotted as a function of the simulated IRE for all patients (figure 3.6). To produce each
curve, the true classification rate values resulting from the thousand IRE simulations
per patient were first binned according to median tumour voxel IRE (1-mm bins).
The median true classification rates within each bin were then plotted against the
median tumour voxel IRE for the A-PRMs as well as for the maps corresponding to
the bounds of the confidence intervals (A-PRM− and A-PRM+).
True classification rates for the PRM and A-PRM decreased with increasing IRE
for all patients but at different rates suggesting the need for patient-specific analysis
of PRM uncertainty due to IRE. A-PRM+ maps improved identification of increasing
and decreasing voxels at the cost of decreased identification of no change voxels.
Conversely, A-PRM− maps provided improved identification of no-change voxels
at the cost of decreased identification of increasing and decreasing voxels. True in-
creasing rates were found to be more sensitive to IRE than the true decreasing or
true no change rates for the investigated image data.
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Figure 3.6: True classification rates with respect to the T95 threshold for the original
PRM method and the A-PRM method plotted as a function of simulated rigid IRE
for the four glioma and HCC cases. The true classification rate represents the fraction
of the total voxels that belong to a given class that are correctly identified as such by
the classification method.
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Table 3.1: Median difference between A-PRM and PRM true classification rates (A-
PRM rates subtract PRM rates) for all glioma simulations, binned by median tumour
voxel image registration error. The indicated range contains 95% of all values within
each bin. Median differences between PRMexp and the PRM are also shown for
comparison.
Median tumour voxel IRE
Class 0-2 (mm) 2-4 (mm) 4-6 (mm)
A-PRM+ inc 0.19 [ 0.06, 0.28] 0.08 [0, 0.19] 0.02 [-0.04, 0.12]
nc -0.05 [-0.11,-0.01] -0.03 [-0.09, 0] -0.01 [-0.08, 0.02]
dec 0.11 [ 0.04, 0.15] 0.10 [0.05, 0.14] 0.08 [0.02, 0.13]
A-PRM inc -0.01 [-0.06, 0.02] -0.03 [-0.08, 0.01] -0.04 [-0.09, 0.01]
nc 0.02 [0, 0.05] 0.03 [0.01, 0.07] 0.04 [0.01, 0.08]
dec 0.01 [-0.01, 0.03] 0.01 [-0.02, 0.04] 0.02 [-0.03, 0.05]
A-PRM− inc -0.18 [-0.30,-0.07] -0.12 [-0.22,-0.02] -0.09 [-0.16,-0.01]
nc 0.05 [ 0.01, 0.12] 0.06 [0.02, 0.13] 0.07 [0.02, 0.14]
dec -0.10 [-0.14,-0.06] -0.08 [-0.12,-0.04] -0.05 [-0.11,-0.01]
PRMexp inc 0.21 [ 0.03, 0.36] 0.15 [-0.08, 0.38] 0.08 [-0.06, 0.40]
nc -0.15 [-0.47,-0.03] -0.26 [-0.53,-0.08] -0.31 [-0.53,-0.09]
dec 0.11 [ 0.02, 0.21] 0.11 [-0.06, 0.23] 0.06 [-0.14, 0.26]
Patient simulation results were then pooled together (independently for each
group) and the median differences in true classification rates between the A-PRM
and PRM methods (A-PRM subtract PRM) were computed within three IRE bins:
0-2 mm, 2-4 mm and 4-6 mm. Tables 3.1 and 3.2 summarize the median differences
by IRE bin for the glioma and HCC groups respectively. For comparison, median dif-
ferences were also computed between the PRMexp and PRM true classification rates
within each IRE bin.
A priori, all table 3.1 and 3.2 median differences were expected to be statistically
significant due to the large number of simulations performed (1,000). To confirm
this, repeated Wilcoxon signed-rank tests with a Bonferroni correction for multiple
comparisons were performed to test for significance. Indeed, all median differences
in tables 3.1 and 3.2 were found to be significant for both patient groups (p < 0.001)
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Table 3.2: Median difference between A-PRM and PRM true classification rates for
all HCC simulations, binned by median tumour voxel image registration error. The
indicated range contains 95% of all values within each bin. Median differences between
PRMexp and PRM are also shown for comparison.
Median tumour voxel IRE
Class 0-2 (mm) 2-4 (mm) 4-6 (mm)
A-PRM+ inc 0.16 [0.06, 0.21] 0.15 [0.05, 0.21] 0.10 [0, 0.18]
nc -0.03 [-0.09,-0.01] -0.02 [-0.09, 0] -0.02 [-0.08, 0.01]
dec 0.06 [0.03, 0.08] 0.06 [0.04, 0.11] 0.06 [0.03, 0.11]
A-PRM inc 0 [-0.05, 0.04] -0.01 [-0.11, 0.05] -0.01 [-0.09, 0.05]
nc 0.01 [0, 0.03] 0.01 [0.01, 0.05] 0.02 [0.01, 0.06]
dec 0 [-0.02, 0.01] 0 [-0.02, 0.03] 0 [-0.02, 0.03]
A-PRM− inc -0.17 [-0.29,-0.10] -0.15 [-0.29,-0.09] -0.12 [-0.18,-0.06]
nc 0.03 [0.01, 0.09] 0.04 [0.01, 0.12] 0.05 [0.02, 0.12]
dec -0.06 [-0.09,-0.04] -0.06 [-0.10,-0.04] -0.06 [-0.09,-0.03]
PRMexp inc 0.17 [0, 0.33] 0.24 [-0.07, 0.39] 0.25 [-0.08, 0.44]
nc -0.07 [-0.35, 0.02] -0.15 [-0.45,-0.06] -0.23 [-0.43,-0.10]
dec 0.03 [0, 0.08] 0.03 [-0.11, 0.11] -0.02 [-0.19, 0.13]
with the exception of table 3.2 A PRM increasing class for the 0-2 mm IRE bin and
the table 3.2 A-PRM decreasing class for the 2-4 mm IRE bin (p > 0.05).
For the figure 3.6 simulations, the median A-PRM classification (median value
of i) was computed for the increasing and decreasing voxels that were misclassified
due to IRE. Results were aggregated for each patient group and binned by IRE
(table 3.3). The purpose of this sub-analysis was to assess the magnitude of A-
PRM misclassification for voxels that should have been classified by the original PRM
threshold (T95) but were misclassified by other Ti due to IRE.
3.4.2 Sensitivity to IRE Estimation
The median A-PRM true classification rates resulting from different under or over-
estimations of the known tumour voxel IRE were then computed for each IRE bin.
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Table 3.3: Median A-PRM classification for voxels that should have been classified
by the original PRM threshold (T95) but were misclassified due to IRE. Simulation
results were aggregated within each group and binned by IRE. The indicated range
contains 95% of all values within each bin.
Median A-PRM classification
Median tumour voxel IRE
True Class 0-2 (mm) 2-4 (mm) 4-6 (mm)
Gliomas 95 68 [-84, 94] 44 [-95, 93] 25 [-95, 92]
-95 -87 [-94, 40] -85 [-94, 41] -85 [-94, 39]
HCC 95 78 [-22, 94] 67 [-41, 94] 49 [-59, 93]
-95 -88 [-94, 95] -85 [-94, 95] -83 [-94, 93]
Results were aggregated for all patients within each patient group and are plotted
in figure 3.7. Each line corresponds to a different IRE bin. Each IRE estimate was
defined by increasing or decreasing the known 99th percentile of the voxel IRE in
each coordinate direction by the amount specified by the horizontal axis.
3.4.3 Generalized A-PRM analysis
For the analysis of the generalized A-PRM (|D(x)|+ aσIRE(x) ≥ Ti), the simulations
for the patients within each group were again pooled together and then binned by
IRE. The median true classification rates within each IRE bin were computed for each
definition of the generalized A-PRM corresponding to different values of the constant
a. The true classification rates with respect to the T95 threshold were then plotted
versus a independently for each IRE bin (figure 3.8).
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Figure 3.7: Influence of under/over estimation of the IRE on the A-PRM true classi-
fication rates aggregated for the four glioma and HCC cases. Each line corresponds
to a different IRE bin and the horizontal axis indicates the amount of under/over
estimation of the IRE in each coordinate direction. True classification rates were
calculated with respect to the PRM threshold (T95).
Figure 3.8: Influence of the parameter a on the true classification rates for the gen-
eralized A-PRM method. Results for a = 3, a = 0, and a = 3 correspond to the
originally proposed A-PRM−, A-PRM, and A-PRM+ maps respectively. For refer-
ence, the median performance of the PRM (circle marker) and PRMexp (x marker)
are indicated for each IRE bin.
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3.5 Discussion
The PRM shows potential as a method for guiding personalized locally adaptive treat-
ment strategies such as sub-volume boosting or dose-painting by numbers. However,
in the present study we have shown that IRE can lead to patient-specific tumour
voxel misclassification which could pose challenges for the reliable guidance of RT.
Since uncertainty management is a critical component of the RT workflow, our goal
was to extend the PRM to permit identification of IRE-related analysis uncertainty
with a view towards determining if it has the potential to influence target delineation.
Our approach involved using a simple Gaussian IRE model to determine the expected
response value of each voxel (A-PRM) as well as estimate a confidence interval to re-
flect the analysis uncertainty caused by IRE (A-PRM−, A-PRM+). Multiple graded
classification thresholds were also incorporated to facilitate visual assessment of IRE-
related analysis uncertainty and regional tumour response trends (§3.2.5). Here we
will discuss the potential utility of the A-PRM for guiding adaptive RT followed by
a discussion of the study limitations.
First, through the use of multiple graded thresholds, the A-PRM provided addi-
tional contextual information related to the regional functional changes occurring in
the cases shown in figure 3.4. For example, in glioma-3 and HCC-3, distinct sub-
volumes of functional increase and decrease became apparent. While voxels within
these regions may be classified by thresholds less than T95 (the threshold typically
correlated with response), the graded threshold information may be useful because it
highlights the location of relatively homogeneous regions of response or progression
which could be used to define adaptive RT targets. In addition, the table 3.3 results
suggest that the A-PRM misclassifies voxels due to IRE in a graded fashion (i.e.
voxels are misclassified by slightly lower or higher thresholds). This is in contrast to
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the PRM method where misclassification (due to IRE) is more severe. For example,
an increasing voxel can only be misclassified as no change or decreasing within the
original PRM.
The homogeneous regions of response visualized using the graded thresholds in
the A-PRM were also observed to be less susceptible to the influence of IRE. Qualita-
tively, this can be appreciated upon inspecting the magnitude differences between the
A-PRM and A-PRM+ and A-PRM− maps shown in figure 3.5. Analysis uncertainty
was the greatest for voxels that were close to feature boundaries in the A-PRM, under-
scoring the relationship between increased analysis heterogeneity and IRE influence.
For example, non-zero magnitude differences in the glioma case were located along
the boundaries of the outer blue and red rims in the A-PRM. In contrast, the analysis
uncertainty was the least (i.e. small magnitude differences) for voxels that were far
away from feature boundaries. This can be observed in the center of the tumour
where there are no distinct features and A-PRM analysis is more homogeneous.
In practice, if potential targets would be substantially different based on using A-
PRM+ versus A-PRM− maps then it could be decided that the IRE related analysis
uncertainty was too high to permit reliable guidance of RT for that patient. However
within this context, several different approaches for adapting the radiotherapy target
could be taken using the different A-PRM maps. For example, A-PRM+ could be
used to ensure that progressing tumour regions are not missed due to IRE. A-PRM+
was designed to improve detection of increasing and decreasing voxels at the cost
of misclassifying no change voxels as changing (figure 3.6 and tables 3.1 and 3.2).
Therefore if within organ at risk dose limits, radiation dose could be escalated to
regions identified as progressing with the understanding that non-progressing tumour
voxels might also receive a higher dose.
This approach may be well-suited to the specific patient image data investigated
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within this study due to their high sensitivity to IRE with respect to classification
of increasing voxels (figure 3.6). This increased sensitivity was due to the lower
number and more spatially diffuse nature of the increasing voxels in the investigated
image data when compared to the decreasing and no change voxels (i.e. decreased
feature size relative to the IRE). The simple spatial margin approach used to create
PRMexp produced results similar to A-PRM
+. However, tables 3.1, 3.2 and figure 3.8
indicated that as IRE was increased, the true no-change rate for PRMexp dropped
off much faster than for A-PRM+, suggesting limited utility for the spatial margin
approach.
Conversely, A-PRM− was designed to improve detection of no-change voxels at
the cost of misclassifying increasing or decreasing voxels as no-change (figure 3.6 and
tables 3.1 and 3.2). This reduces the likelihood that voxels are misclassified as increas-
ing or decreasing due to IRE, but reduces the total number of the actual increasing
and decreasing voxels detected. Therefore dose could be modified using the A-PRM−
with the understanding that treatment only deviates away from conventional non
adaptive dose distributions where the image analysis is known to be less influenced
by IRE.
Ultimately, the ability to locally adapt RT is limited by the size of the regions to
be adapted relative to the radiation targeting capabilities of the treatment machine.
With this constraint in mind, the delivery of boost doses to progressing tumour sub-
volumes will be an important first step towards locally adapted RT. Previously we
discussed how increased analysis heterogeneity increases the influence of IRE. Regions
of homogeneous analysis that are large enough to be treated with a sub-volume boost
in practice (e.g. 1-2 cm) may be fairly robust to the influence of moderate magnitudes
of IRE (e.g. 2-4 mm). If they exist, these regions are easily identified on the A-PRM
due to the use of the multiple graded classification thresholds. Therefore, the A-PRM
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should be well suited towards defining sub-volume boost targets within contexts where
standard PRM analysis has been correlated with a measure of treatment response. A
retrospective RT planning study of the technical feasibility and potential benefit of
radiation delivery to these sub-volumes constitutes an important next step towards
implementing locally adaptive radiotherapy using the A-PRM.
A key limitation of the current A-PRM method is the use of the simple Gaussian
error model to define the IRE probability distribution function. There are two major
drawbacks to this approach.
First, the user must provide an estimate of the IRE anticipated within the tumour.
While this is feasible through identification of anatomically corresponding fiducials in
the registered images (e.g. De Silva et al. [23]), it can present a labor-intensive task.
In practice a single suitably conservative estimate may need to be determined which
represents an upper bound for the IRE anticipated for the majority of patients scanned
and registered with the same technique. The standard RT workflow adopts a similar
approach with respect to managing uncertainty in the delineation and position of
planning target volumes. However, in figure 3.7 we observed that IRE overestimation
reduces detection of increasing and decreasing voxels while increasing detection of
unchanging voxels. Therefore depending on the images, use of a single over-estimated
value of the IRE may obscure some of the significantly changing tumour regions
classified by T95. Despite this effect, regional response trends should still be observable
in the A-PRM due to the use of multiple graded classification thresholds.
Second, the IRE PDF is defined to be independent, constant and symmetric about
a zero mean IRE for all voxels within a pair of registered image volumes. This consti-
tutes a first order approximation since the true but unknown IRE PDF will vary for
each voxel depending on the proximity of the voxel to image features that are salient
to the algorithm used for registration. The IRE PDFs for adjacent voxels may also be
97
highly inter dependent due to the regularization of the deformation field. Since a sin-
gle upper estimate of the voxel-wise IRE is used to define the IRE PDF, the influence
of IRE will be over-estimated for many voxels. Other error models (statistical dis-
tributions) apart from a Gaussian model could be considered. However, such models
would exhibit similar limitations such as spatial invariance and under-representation
of IRE complexity. Other models would also introduce different assumptions about
the underlying IRE distribution (e.g. non-symmetric, direction-bias) that may or
may not be valid throughout the analyzed ROI.
An advantage of this simple model-based approach is that it provides the user with
a highly accessible method to rapidly probe the influence of IRE on their analysis.
The A-PRM can be updated in near real time as the user tests the effects of different
anticipated IRE magnitudes. In addition, the simple Gaussian error model can easily
be applied to voxel based analyses other than the A-PRM in order to estimate the
potential influence of IRE. Despite its simplicity, this first order approach was also
demonstrated by 3.1, 3.2 and the generalized A-PRM analysis to provide some small
improvements to classification performance for decreasing and no change voxels.
Nonetheless, improved local estimation of the IRE PDF should further improve A-
PRM classification in the presence of IRE. Several promising registration algorithms
have been proposed which seek to estimate an optimal transformation as well as
its associated uncertainty [9, 11, 13–16]. In particular, the probabilistic registration
framework proposed by Risholm et al. [9] may be an ideal candidate for improved
local estimation of the IRE PDF.
While the present study focuses on voxel-wise classification accuracy, it would
be interesting to investigate if improved voxel-wise classification also improves pre-
diction of global treatment response measures like overall survival. The A-PRM
classifies each voxel based on the expected value of a distribution of intensity dif-
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ferences estimated for each voxel using a Gaussian error model. In contrast, the
original PRM method classifies each voxel based on a single observed difference from
this distribution. Therefore, provided that the Gaussian error model is a reasonable
approximation to the underlying IRE distribution, we hypothesize that the A-PRM
would more accurately reflect the true voxel intensity differences in the presence of
IRE. However, as previously discussed, the Gaussian error model may not accurately
reflect the true IRE distribution. Furthermore, global treatment response prediction
using the PRM, and by extension A-PRM, involves an aggregate analysis of a large
number of voxels (e.g. computing fractional volumes) and may already be robust to
IRE. Therefore we hypothesize that the A-PRM may not significantly improve global
treatment response prediction.
Our testing strategy involved comparing results against a “ground truth” PRM
analysis performed on the initial non-rigidly registered data. Therefore resulting
analyses may have been influenced by residual IRE from the non rigid registration. An
alternative approach would involve artificially creating the follow-up functional images
by simulating treatment related functional changes in the baseline images. While
this would ensure perfect alignment, it would be challenging to simulate realistic
treatment related tumour functional changes since they are not yet well understood.
Therefore the former method was adopted as the closer approximation. While rigid
IRE simulation results were reported here to demonstrate the efficacy of the A-PRM
method, we have also performed non-rigid IRE simulations in parallel and observed
very similar classification results. Therefore for the sake of clarity, we focused on rigid
IRE within the present proof-of-principle study. However, owing to the complexity
of non-rigid IRE simulation, a follow-up study investigating non-rigid IRE may be
appropriate.
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3.6 Conclusion
The A-PRM was demonstrated to help visualize and quantify the influence of IRE on
parametric response map analysis. The augmented method provided additional con-
textual information including image registration uncertainties which could facilitate
the definition of targets for locally adaptive radiotherapy (e.g. sub volume boosts).
Upper and lower bound response map estimates show promise as useful tools for prob-
ing the local influence of anticipated IRE on analysis. The A-PRM method should
facilitate reliable use of PRM analysis for guiding adaptive RT by allowing the user to
identify in advance whether a patient’s unique IRE-related PRM analysis uncertainty
has the potential to influence RT target delineation.
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Chapter 4
A generalized approach towards
multi-parametric response mapping using
principal component analysis ∗
4.1 Introduction
The development of early treatment response prediction methods represents an impor-
tant step towards improving cancer care via personalized adaptive treatment strate-
gies. Once identified, ineffective treatments could be adapted, halted, or alternative
therapies could be considered to improve patient outcomes or reduce toxicities. Such
an approach may be of particular interest for aggressive cancers such as glioblas-
toma multiforme where there is a limited therapeutic window and treatments may be
associated with significant toxicity [1].
Parametric response mapping (PRM) has emerged as a powerful image-analysis
technique which can be used to predict early treatment response [2]. Typically, PRM
analysis involves a voxel-wise comparison of longitudinally acquired and spatially-
∗This chapter is adapted from the manuscript entitled “A generalized approach towards multi-
parametric response mapping using principal component analysis.” This manuscript is in preparation
for submission to the journal Medical Physics.
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aligned functional images. Tumour voxels are classified as increasing, decreasing, or
not changing in function. The fraction of the tumour volume associated with one of
these classes may then be found to correlate with a global measure of response such
as overall survival [2]. To date, the predictive utility of the PRM method has been
demonstrated for a variety of different pathologies such as glioblastoma, head and neck
cancer, breast cancer, hepatocellular carcinoma and chronic obstructive pulmonary
disease (COPD) [2–7]. Due to the voxel-wise nature of PRM analysis, this technique
may also have potential for guiding personalized locally adaptive interventions such
as adaptive radiotherapy (RT).
There are several key advantages to the PRM method. First, it involves voxel-
wise image analysis and incorporates spatial correspondences to describe the spatial
heterogeneity in intra-tumour response. Second, the PRM enables intuitive visual-
ization of this heterogeneity. Third, PRM analysis is straightforward to implement
and interpret, providing a uniquely accessible and effective means of probing image
data for treatment response biomarkers.
However to date the PRM method has been almost exclusively applied to longi-
tudinally acquired pairs of single-parameter image data. Galban et al. [8] previously
investigated the benefit of combining two independent single-parameter analyses for
a cohort of patients diagnosed with glioblastoma. Independent PRM analyses were
performed on diffusion and perfusion image data and then the resulting scalar-valued
PRM biomarkers were combined via multivariate logistic regression. This two-variate
approach was shown to improve prediction of overall survival when compared to
PRM analysis of diffusion or perfusion data alone, highlighting the potential of multi-
parametric response prediction. However, since the two PRM analyses were performed
independently, spatial correspondences between the diffusion and perfusion data were
not included in the analysis. Consequently, spatial-heterogeneity in multi-parametric
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treatment response cannot be taken into account nor visualized. Incorporation of
spatial correspondences between functional imaging at two time points was a key
driver of the success of the original PRM method. Therefore, an analogous multi-
parametric approach may have potential for improving treatment response prediction
and assist in finding new treatment response biomarkers. A fully voxel-wise approach
towards multi-parametric treatment response prediction using PRM may also facil-
itate investigation into voxel-wise treatment response prediction for the purposes of
guiding locally adaptive interventions.
Here our goal was to develop a unified multi-parametric response analysis frame-
work which extends the key advantages of the single-parameter PRM method to
analysis of multi-parametric data. We introduce a generalizable N -dimensional ap-
proach towards multi-parametric response mapping (MPRM) which takes spatial het-
erogeneity in multi-parametric response into account and supports visualization and
interpretation of this heterogeneity. For preliminary demonstration, the proposed
method is applied to a multi-parametric image dataset acquired from a group of pa-
tients treated for high-grade glioma. Representative MPRMs and prediction of overall
survival are demonstrated with comparison to single-parameter PRM analyses.
4.2 Materials and Methods
4.2.1 Original PRM: single-parameter response map
The original single-parameter PRM is generated through analysis of temporal voxel-
wise intensity changes between two spatially registered image volumes within some
region of interest (e.g. tumour). Longitudinally acquired functional images of the
same type are typically analyzed. Voxel-wise changes are classified as increasing,
decreasing, or not changing in intensity according to a single threshold value T (de-
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termination of T discussed further below). If ∆I(x) represents the voxel-wise intensity
change for a voxel located at position x within the registered pair of image volumes,
then the intensity change is classified as increasing or decreasing if ∆I(x) > T or
∆I(x) < −T respectively. Voxels where |∆I(x)| ≤ T are classified as not changing.
The PRM itself corresponds to an image of the region of interest (ROI) which indi-
cates the classification of each voxel. The fraction of the ROI volume associated with
one of the classes may then be found to correlate with a measure of global response
(e.g. overall survival) among a patient group [2].
The cut-off threshold T has been determined in several different ways. For ex-
ample, Galban et al. [2] determined T among a cohort of patients with glioblastoma
by analyzing the functional changes in a region of normal tissue on the contralateral
side of the brain with respect to the tumour. Follow-up functional image voxel values
within the normal tissue ROIs were plotted against the spatially corresponding base-
line functional image voxel values. T was then defined as the 95% confidence interval
(CI) in the residuals from a linear fit to this plot. Other studies have successfully
used similar approaches towards threshold determination [3, 5, 8]. Receiver-operator
characteristic (ROC) analysis has also been performed to find thresholds which maxi-
mize the predictive utility of the PRM method with respect to the outcome of interest
[4]. More recently, the variability from single-session test-retest imaging as well as
principal component analysis (PCA) of image intensity histograms have been used
for threshold determination [7, 9].
The PCA-based method proposed within the present study represents a new ap-
proach towards response mapping when compared with the use of PCA in Zha et
al. [9]. In Zha et al., PCA was applied to histograms of lung CT image intensities
from a cohort of patients to derive single-parameter PRM thresholds to classify pa-
tients with airways disease and or emphysema. In contrast, we apply PCA directly to
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co-registered multi-parametric image data (rather than image intensity histograms)
within a normal tissue reference ROI establishing reference principal components
(PC). We then classify candidate image data within a target ROI through projection
onto the principal components established from the normal tissue reference PCA. The
use of PCA within our proposed method is further discussed in section §4.2.2.1-4.2.2.3.
4.2.2 Multi-parametric response map
There are three major components in the MPRM method; i) application of PCA
to image data within a normal tissue reference ROI, ii) classification of data within
a target ROI (e.g. tumour) using the reference PCA, and iii) construction of the
response maps.
The reference PCA represents the MPRM analogue of determining a set of PRM
classification thresholds. The classification of the target data using the reference
PCA corresponds to the PRM step where tumour voxels are classified according to
the threshold determined from normal tissue. Finally, construction of the response
maps involves creating visualizations of the classifications for each voxel. Details for
each of these components follow in §4.2.2.1, §4.2.2.2, and §4.2.2.3 respectively.
The MPRM method can be applied to any multi-parametric image dataset. In
practice, each patient’s data would likely include multiple pairs of longitudinally ac-
quired multi-parametric imaging as a direct extension of the original PRM approach.
For example, an eligible dataset could consist of diffusion and perfusion weighted MRI
acquired before, during, and/or after treatment for each patient. However this is not
an algorithm constraint and any set of images could potentially be analyzed provided
that the same imaging (type, acquisition time points, protocol) is available for each
patient. Similarly there are no algorithm-imposed constraints on the definition of the
reference and target ROIs. However, for clarity in subsequent discussion of methods,
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we will associate the reference ROI with normal tissue and target ROI with tumour
or peritumoral tissue.
Image volumes must be spatially co-registered and resampled to the same array
and voxel size prior to analysis. Since PCA is sensitive to the numerical range of the
input image intensity values, all reference and target image data must be scaled to
a common domain prior to MPRM analysis. Here, we linearly rescale each image so
that its range of voxel values fall between 0 and 1. The potential limitations of this
rescaling and PCA are explored in the discussion section.
4.2.2.1 Reference principal component analysis
The first step in the MPRM method is to use PCA to summarize the typical multi-
parametric voxel values and variance within a normal tissue reference ROI . Figure
4.1 provides an example of a reference PCA as applied to MRI-derived apparent
diffusion coefficient (ADC) and relative cerebral blood volume (rCBV) functional
images acquired 1 month and 3 months post-RT for a patient treated for glioblastoma.
The reference PCA is analogous to the threshold determination step in the orig-
inal single-parameter PRM method. For the original PRM method, follow-up scan
voxel values were plotted against the spatially corresponding baseline scan voxel val-
ues within normal tissue ROIs. Each voxel is then represented by a point in a 2-
dimensional Cartesian space. A line of best fit was used to describe the typical voxel
value pairings and the 95% CI in the fit residuals was used to represent the typical
variance about this line.
For multi-parametric data consisting of N spatially registered image volumes,
voxel intensity values from each of the different image volumes are similarly plotted
along coordinate axes in an N -dimensional Cartesian space. PCA [10] can then be
used to summarize the multi-parametric image data within a reference ROI. In the
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PCA, each of the N images is considered to be a variable and each N -tuple of spatially
corresponding voxel intensity values within the reference ROI is considered to be a
single observation of these N variables. If M is the number of voxels within the
reference ROI, then the data matrix input into the PCA has size MxN where each
column has had its mean value subtracted from it. The output of the PCA is a
set of N eigenvectors {vi} for i = 1 . . . N (principal components) which describe the
primary directions of variance within the reference data plotted in the N -dimensional
Cartesian space. A set of N corresponding eigenvalues {λi} for i = 1 . . . N represents
the variance explained by each principal component (PC).
Figure 4.1 shows an example with N = 4 images (two images 1-month post-RT
and two images 3-months post-RT). The reference data would normally be analyzed
in a 4-dimensional Cartesian space with four PCs output from the reference PCA. It
is possible to plot the data and PCs in 4D and then project into 3D for visualization.
However, a clearer 3D visualization is obtained when we apply PCA to the first three
images in figure 4.1 and plot the resultant data in 3D. Consequently, this is the
approach taken in figure 4.1. In practice, PCA would be applied to all N images.
When positioned at the N -dimensional mean of the reference data, the first PC
corresponds to an N -dimensional linear fit to the plotted reference data, analogous
to the line of best fit used to compute classification thresholds in the original PRM
method. We denote this first PC by v1, a vector in the direction of the line of best
fit. The second PC (v2) is orthogonal to this linear fit and the associated eigenvalue
is equal to the variance of the data about the fit in the direction of the second PC. In
effect, the second eigenvalue λ2 is the sum of squares of the linear fit residuals in the
direction of the second PC. This variance can then be used to determine classification
thresholds similar to the original PRM method where the linear fit residuals were also
used to define a threshold.
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Figure 4.1: Example of a reference PCA as applied to MRI-derived apparent diffusion coefficient (ADC) and relative
cerebral blood volume (rCBV) data acquired at 1 and 3-months post-RT for a patient treated for glioblastoma. The
target ROI (T) is the tumour and the reference ROI (R) is normal tissue on the contralateral side of the brain. Spatially
corresponding voxel values in R are plotted in a Cartesian space and then PCA is used to summarize typical multi-
parametric voxel values and variance within R. To permit 3-dimensional visualization within this figure, only the first
three images are analyzed and so there are only three PCs denoted by v1, v2, and v3 respectively. The ellipses in the
central plot span ±2√λ1, ±2
√
λ2, and ±2
√
λ3 in the direction of the first, second and third PCs respectively (i.e. two
standard deviations).
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Higher order PCs (v3, v4, . . . vN) also describe a proportion of the variance of the
data about the linear fit. However, due to the nature of PCA the proportion of the
data variance described by higher order PCs drops off when there are correlations in
the input data. Therefore thresholds determined from the second PC may summarize
the majority of the variability in the reference data about the N -dimensional linear
fit. Determination of classification thresholds is discussed further in section §4.2.2.2
and §4.2.2.3.
In aggregate, the output of the reference PCA consists of the set of PCs {vi}
positioned at the multi-dimensional mean of the reference data and the corresponding
eigenvalues {λi} for i = 1 . . . N . Similar to the original PRM method, patient-specific
or population-based thresholds can be determined by including the data from one or
more patients in the reference PCA.
4.2.2.2 Target data classification using the reference PCA
The second step in the MPRM method is to use the normal tissue reference PCA
to classify the multi-parametric data within a candidate patient’s target ROI. This
corresponds to the step in the original PRM method where tumour voxels are classified
by the threshold determined from normal tissue. Here, the goal is to classify the target
data in terms of the variability observed along each reference PC. Figure 4.2 provides
an overview of target data classification, expanding on the example considered in
figure 4.1.
First, the multi-parametric voxel values within the patient’s target ROI are plotted
in the sameN -dimensional Cartesian space occupied by the reference data. The target
data are then projected onto the reference PCs to determine the component of each
data point along each of the PC axes. After projection, each target voxel is represented
by a new set of coordinates in a rotated N -dimensional space spanned by the PCs
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and centered about the N -dimensional mean of the reference data. Since the origin of
the space is the N -dimensional mean of the reference data, a target voxel’s coordinate
along a PC axis describes the difference between its multi-parametric value and the
reference data mean (in the direction of the PC axis). Therefore higher magnitude
coordinates identify target voxels as increasingly different from the reference data.
To facilitate comparison of these differences with the variability observed in the
reference data, the coordinates are then normalized by the standard deviation of the
reference data along each PC axis. That is, if xi represents the coordinate of a voxel
along the i-th PC then, xi → xi/
√
λi where λi represents the i-th PC’s associated
eigenvalue (variance) and
√
λi is the standard deviation of the reference data along the
i-th PC. The normalized coordinates describe the difference between the target data
and the mean of the reference data in units of the reference data standard deviation.
For example, normalized voxel coordinates of (1, -2, 3) would indicate that the voxel
is 1, 2, and 3 reference data standard deviations away from the reference data mean
in the direction of the first, second and third PCs respectively. The negative sign on
the second coordinate indicates that the voxel is positioned on negative side of the
PC axis with respect to the reference data mean.
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Figure 4.2: Classification of the target data (red) using the reference PCA (ellipses) from the glioblastoma example from
figure 4.1. The first, second, and third reference PCs are denoted by v1, v2, and v3 respectively. The multi-parametric
target data are plotted in the same space as the reference data, projected onto the reference PCs and then re-expressed in
terms of PIs along each PC. Ellipses in the first two plots span ±2√λ1, ±2
√
λ2, and ±2
√
λ3 in the direction of the first,
second and third reference PCs respectively (i.e. two standard deviations).
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After normalizing by the standard deviation of the reference data along each PC,
the coordinates are re-expressed in terms of reference data prediction intervals (PIs).
Using the previous example, the coordinate (1, -2, 3) can be re-expressed as (66.8, 95,
99.7) indicating that the target voxel’s multi-parametric intensity values fall within
the central 66.8%, 95% and 99.7% of the reference data variation along each PC under
the assumption of normally distributed reference data. The PIs can be computed by
using the standardized target data coordinates to sample a unit normal distribution.
Finally, we set the signs of the new PI-based coordinates to be equal to the signs of
the earlier standardized coordinates to convey whether the voxel is positioned on the
positive or negative side of each PC axis with respect to the reference data mean.
That is, (66.8, 95, 99.7) → (66.8, -95, 99.7). The second coordinate, -95, indicates
that the target voxel is within the 95% PI of the reference data along the second PC
and is positioned on the negative side of the PC axis with respect to the reference
data mean (i.e. with respect to the origin of the space).
4.2.2.3 Response map construction
The final step in the MPRM method is to construct response maps which visualize
the target data that has been classified (re-expressed) in terms of the PIs from the
reference PCA. In principle, N separate MPRMs could be constructed which visualize
the PI classifications of the target voxels along each PC. That is, a separate MPRM
could be constructed from the first coordinate of the re-expressed target data, the
second coordinate of the re-expressed target data, and so on. Each of these MPRMs
would classify and visualize the full distribution of the target data since every voxel
is identified by its own PI-based coordinates. Figure 4.3 illustrates the construction
of response maps expanding upon the example in figures 4.1 and 4.2.
For simplicity, a single MPRM should be proposed for prediction. We will discuss
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Figure 4.3: Response map construction from the re-expressed target data in figure
4.2. Three separate MPRMs can be constructed, MPRMv1 , MPRMv2 and MPRMv3
which visualize the target voxel coordinates (PI classifications) along the principal
component axes v1, v2, and v3 respectively. MPRMs are shown superimposed on the
patient’s T1-weighted MRI scan.
candidates MPRMv1 , MPRMv2 and maps built from higher order PCs. MPRMv1
is built from target data coordinates along the first PC of the reference PCA. For
each target voxel, it describes the distance between the position of that voxel and
the mean of the normal tissue reference data within the N -dimensional Cartesian
space (in the direction of the first PC). Therefore differentiation of responding and
non-responding patients using MPRMv1 would require one group’s target data to be
clustered significantly closer or further away from the other group with respect to
a single point (mean of the reference data) in the Cartesian space. However, early
treatment response prediction is challenging precisely because responding and non-
responding patients do not exhibit significant differences in the mean tumour voxel
image intensities. Therefore the predictive potential of MPRMv1 may be limited.
To address this challenge, the original single-parameter PRM method instead
compared the variability in tumour functional images to variability observed in normal
tissue as described by the cut-off threshold T (95% CI in linear fit residuals)[2].
An MPRM built from the second PC of the reference PCA provides an analogous
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approach to the PRM. For each target voxel, MPRMv2 describes the distance between
the position of that voxel (in the direction of the second PC) and the N -dimensional
linear least squares fit defined by the first PC from the reference PCA. That is,
MPRMv2 describes the variation of the target data about a linear fit to the reference
data. Similar to the original PRM, MPRMv2 expresses (and classifies) this target
data variation in terms of PIs for the residuals of the reference data about this linear
fit. Therefore MPRMv2 provides a comparison of the variability of the target and
reference data about the first PC (in the direction of the second PC).
MPRMs built from higher order PCs (i.e. MPRMv3 . . .MPRMvN ) also compare
the variation of the target and reference data about the first PC. However provided
that the input data is not completely uncorrelated, the proportion of the reference
data variance explained by higher order PCs drops off due to the nature of PCA.
Consequently, MPRMv2 may represent a comparison of the target data variability
to the majority of the reference data variability eliminating the need to consider
higher order MPRMs. Therefore within this study we chose to investigate MPRMv2
for the purpose of treatment response prediction. We discuss the limitations of this
approach and propose alternative methods incorporating multiple higher order PCs
in the discussion section. Example MPRMs built from other PCs are also provided
for the purposes of demonstrating the MPRM method.
4.2.3 Demonstration
For demonstration, MPRM analysis was applied to a multi-parametric image dataset
acquired from a group of 19 patients treated for high-grade glioma. MRI-derived ADC
and rCBV maps acquired at 1 and 3 months post-treatment were analyzed. Represen-
tative MPRMs and prediction of overall survival are demonstrated with comparison
to single-parameter PRM analyses.
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4.2.3.1 Patient and image data
This study was performed in compliance with institutional research ethics boards and
informed consent was obtained from all patients. Multi-parametric imaging from a
total of 19 patients diagnosed with World Health Organization grade IV glioblastoma
(n = 17), grade III anaplastic oligodendroglioma (n = 1) and grade III anaplastic
astrocytoma (n = 1) were analyzed. All patients were treated with surgery followed
by radiotherapy (RT) with concurrent and adjuvant temozolomide chemotherapy. For
RT, 18 patients received 60 Gy in 30 fractions while one patient received 45 Gy in 15
fractions with a 24 Gy stereotactic boost delivered in 3 fractions. The median age at
the time of diagnosis was 65 years (range, 31-81 years) and median overall survival
(OS) was 18.2 months (range, 4.7-41.6 months).
MR imaging acquired at 1 and 3 months post-radiotherapy was available for each
patient. Scans were acquired with a 1.5 T Signa HDXT (GE Healthcare, Milwaukee,
WI) or a 1.5 T Achieva scanner (Philips Medical Systems, Best, The Netherlands).
Imaging at both time points included post-gadolinium axial T1-weighted, diffusion
weighted, and dynamic-susceptibility contrast-enhanced (DSC) scans. ADC maps
were generated from the diffusion-weighted images which were acquired with b-values
of 0 and 1000 s/mm2. CBV maps were generated from the DSC scans using the
method by Boxerman et al. which corrects for contrast agent extravasation [11]. Each
CBV map was converted to a rCBV map via normalization by the mean intensity
within 15 white-matter ROIs placed on the contralateral side of the brain with respect
to the tumour. Each white-matter ROI was circular and approximately 1 centimeter
in diameter. Figure 4.4 shows example imaging for patients with short and long OS.
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Figure 4.4: Post-gadolinium T1-weighted MRI, ADC, and rCBV maps at 1 and 3
months post-RT for a patient with (a) OS = 11 months and (b) OS = 41 months.
The outline of PERIPH is indicated for each patient. The outline of the CEL is also
implicitly shown by PERIPH. ADC maps are expressed in units of 10−3mm2/s
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4.2.3.2 Image registration and segmentation
For each patient, all T1, T2, DWI, and DSC images were rigidly registered using
3D Slicer (BRAINS module)[12]. The scans for each patient were also resampled
to a common image array and voxel size to facilitate voxel-wise analyses. The final
image array size varied between patients depending on their individual scan protocol;
however, voxel sizes were resampled consistently across patients with a final size of
1 mm by 1 mm by 5 mm in the left-right, anterior-posterior and superior-inferior
directions respectively. ADC and rCBV maps were registered indirectly by applying
the transformations output from registration of the source images from which they
were derived.
After registration, the post-gadolinium T1-weighted images were used to delineate
the contrast-enhancing lesion (CEL) at the 1 and 3-month post-RT time points. CEL
contours were delineated by AL, revised by an experienced glioblastoma imaging re-
searcher (TY), and then verified by a radiologist with 8 years of experience (YW). As
shown in figure 4.4, an ROI encompassing a 1 cm isotropic margin around the periph-
ery of the CEL (PERIPH) was also generated. The original CEL was excluded from
the expanded ROI. PERIPH ROIs were then manually adjusted to ensure ventricles
and regions outside of the brain were not included in the final ROIs. Finally, a spher-
ical ROI (2 cm diameter) containing white matter was defined on the contralateral
side of the brain with respect to the tumour for each patient. This ROI was defined
independently of the white matter ROIs used to produce the rCBV maps.
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4.2.3.3 Parametric response mapping
Table 4.1 provides a summary of the parametric response mapping performed for
each patient. A total of eight PRMs and four MPRMs were generated per patient,
including special analyses related to mitigation of image registration error (IRE)
related analysis uncertainty. Discussion within this section is organized according to
the headings of the table from left to right.
For all PRM and MPRM analyses, population based PRM thresholds and MPRM
reference PCAs were generated using image data from the normal white matter ROIs
delineated on the contralateral side of the brain with respect to the tumour. These
ROIs were selected to be the MPRM reference regions since they included relatively
homogeneous voxel intensities (plus noise). This increases the normality of the data
input into the reference PCA when compared to alternative regions containing multi-
ple tissue types with non-homogeneous image intensity values. While data normality
is not a strict requirement of PCA, it improves the ability of PCA to describe the in-
put data. Furthermore, we compute prediction intervals to classify target data based
on an assumption of normality in the reference data residuals about the reference
PCs.
Two target ROIs were independently investigated per patient. The spatially in-
tersecting CELs defined at 1 and 3 months post-RT were first compared to the white
matter ROI followed by the spatially intersecting PERIPH ROIs. PERIPH was in-
vestigated in addition to the CEL since increased rCBV values in the peritumoral
region have previously been associated with decreased OS [13].
For each of the target ROIs, separate PRM analyses were performed based on
the longitudinally-acquired pairs of ADC and rCBV image data. That is, a PRM
analysis was performed on the 1 and 3-month ADC data (ADC1, ADC3) followed by
a separate PRM analysis of the 1 and 3-month rCBV data (rCBV1, rCBV3). MPRM
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analysis was performed using all of a patient’s 1 and 3-month ADC and rCBV images.
Finally, for each combination of method, target, and image data, we investigated the
effect of using Gaussian blurring to combat image registration error (IRE) related
uncertainty [14]. Blurring was performed using an isotropic 3-dimensional Gaussian
kernel where 3σ = IREmax along each coordinate direction. For simplicity in the
present discussion, we selected IREmax = 3 mm which corresponds to an assumption
that 99.7% of the IRE along each coordinate direction is within 3 mm or alternatively
that 99.7% of the total IRE is within approximately 5 mm.
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Table 4.1: Summary of parametric response mapping analyses performed. Subscripts 1 and 3 on CEL, PERIPH, ADC,
and rCBV abbreviations denote 1 and 3-month post-RT respectively. CEL denotes the contrast enhancing lesion and
PERIPH denotes a 1-cm-thick shell in the peritumoral region immediately around the CEL. To facilitate subsequent
discussion, PRM analyses are labelled P1 through P8 and MPRM analyses are labelled M1 through M4.
Method Reference Target Image Data IRE blurring (mm) Analysis label
PRM white matter CEL1 ∩ CEL3 ADC1, ADC3 0 P1
3 P2
rCBV1, rCBV3 0 P3
3 P4
PERIPH1 ∩ PERIPH3 ADC1, ADC3 0 P5
3 P6
rCBV1, rCBV3 0 P7
3 P8
MPRM white matter CEL1 ∩ CEL3 ADC1, ADC3, rCBV1, rCBV3 0 M1
3 M2
PERIPH1 ∩ PERIPH3 ADC1, ADC3, rCBV1, rCBV3 0 M3
3 M4
123
4.2.3.4 Response prediction and analyses
Similar to previous studies [2–4, 6, 7], the fractional volume of each patient’s target
ROI classified as increasing, decreasing, or not changing in function was computed for
each of the PRM and MPRM analyses. As discussed in §4.2.2.3, only MPRMs built
from the second PC of the reference PCAs were investigated for predictive potential.
For PRM analyses, the threshold used to classify voxels as increasing, decreasing
or not changing in function was determined similar to Galban et al. [2], where the
95% CI in the linear fit residuals defined a single value of T for the entire patient
group. However, in addition we employed a leave-one-out strategy to find the CI-
based threshold which maximized the Pearson correlation of PRM-derived fractional
volume measures with overall survival. This threshold was then used to classify voxels
as increasing, decreasing, or not changing in order to generate PRMs for each of the
19 patients. Since a leave-one-out analysis was used, PRM classification thresholds
were patient-specific. The algorithmic details of the leave-one-out method used to
determine the classification threshold for each patient are as follows:
1. Define threshold training set to include n = 18/19 patients leaving out one
patient.
2. Generate 100 PRMs for each patient in the training set using the 0%, 1% . . .
99% CIs in the linear fit residuals as thresholds.
3. Compute the fractional volume classified as increasing, decreasing, or not chang-
ing for each patient’s 100 PRMs. Each threshold is then associated with an 18
(number of patients) by 3 array (number of PRM classes) array of fractional
volume values.
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4. For each threshold, compute the Pearson correlation between the fractional
volume measures and overall survival within the training set (independently for
each class) producing a 100 (number of thresholds) by 3 (number of classes)
array of correlation values.
5. For each PRM class, select the threshold that elicited the highest correlation
with overall survival (i.e. three thresholds selected). Each of the selected thresh-
olds, when used to generate PRMs in the training set, maximizes the correlation
of either the increasing, decreasing, or no change fractional volume measures
with overall survival.
6. Compute three PRMs for the patient left out of the training set based on the
three classification thresholds selected in step 5.
7. Repeat steps 1-6 leaving a different patient out of the training set each time
resulting in 3 sets of 19 PRMs. Each set maximizes the correlation of either
the increasing, decreasing, or no change fractional volume values with overall
survival.
The n = 19 patients were then split into two groups, responders (n = 10) and non-
responders (n = 9) according to whether OS ≥ 18.2 months (median OS). One of the
three sets of PRMs produced in step 7 was chosen for further analysis. The set which
maximally separated the responding and non-responding patients’ fractional volume
values according to repeated Wilcoxon rank-sum tests was selected.
To predict OS ≥ 18.2 months, a simple threshold approach was employed whereby
patients were classified as responders or non-responders according to whether their
fractional volume measures were above or below a cut-off value which was varied
in an ROC analysis. Classification sensitivity, specificity, accuracy and area under
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the curve (AUC) values were computed for each analysis. All ROC analyses were
performed using SPSS (IBM SPSS, version 20.0, Chicago, IL).
MPRMs were converted to 3-class maps (i.e. increasing, no change, decreasing)
by selecting a single PI along the 2nd PC as a cut-off threshold. Similar to the PRM
algorithm detailed above, a leave-one-out optimization was performed on the MPRMs
to find a threshold which maximized correlation of MPRM-derived fractional volume
measures with overall survival. Within the context of these MPRM analyses, increas-
ing or decreasing implies that a voxel’s multi-parametric voxel values are located on
the positive or negative side of the 2nd PC axis with respect to the reference data
mean. Prediction of OS ≥ 18.2 months using the MPRMs was then performed in
the same way as PRM-based prediction (i.e. simple threshold classification and ROC
analysis).
4.3 Results
Multiple PRMs and MPRMs were generated from the ADC and rCBV data for the n
= 19 glioma patients according to the analyses detailed in section 4.2.2.3 and table 4.1.
Figure 4.5 illustrates examples of single-parameter PRMs for the two patients shown
in figure 4.4. For demonstration, the 95% CI in the linear fit residuals was used to
define a significance cut-off threshold for this figure. Separate analyses were performed
in the intersection of the 1 and 3-month post-RT CEL (first row) and the intersection
of the 1 and 3-month post-RT PERIPH (second row). The intersection of the 1 and
3-month CELs in figure 4.5a appears to exclude centrally located CEL. However, after
careful inspection (e.g. windowing and leveling, comparison to adjacent slices) the
radiologist judged this central region to be non-enhancing based on their experience.
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Figure 4.5: Original single-parameter PRMs generated from the ADC and rCBV
image data from figure 4.4 for two patients with (a) short and (b) long OS. Analysis
was performed within CEL1 ∩ CEL3 (first row) and PERIPH1 ∩ PERIPH3 (second
row) and superimposed on the 1 month post-RT T1-weighted scans.
For all MPRM analyses, the multi-parametric image data within white matter
ROIs defined on the contralateral side of the brain of all 19 patients were used to
perform population-based reference PCAs. Table 4.2 summarizes each of the PCs
and associated eigenvalues from this reference PCA.
MPRMs generated for the two patients from figure 4.5 are shown in figure 4.6.
Similar to the didactic example from figure 4.3, maps generated from the PI classifi-
cations along each PC of the reference PCA are shown for demonstration. MPRMv1 ,
MPRMv2 , MPRMv3 , and MPRMv4 correspond to the maps generated from classifi-
cation along the first through fourth PCs of the reference PCA respectively. Quali-
tatively, MPRMv2 , and MPRMv4 appear notably different in figure 4.6 between the
patients with short and long OS.
The fractions of the target ROIs (CEL and PERIPH) classified as increasing, de-
creasing, or not changing were computed for each of the PRM and MPRMv2 analyses
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Figure 4.6: MPRMs generated from the 1 and 3-month post-RT ADC and rCBV
image data from 4.4 with (a) short and (b) long OS. Analysis was performed within
CEL1 ∩ CEL3 (first row) and PERIPH1 ∩ PERIPH3 (second row) and superimposed
on the 1 month post-RT T1-weighted scans.
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Table 4.2: Reference PCA principal component vectors (v1 . . . v4) and corresponding
eigenvalues.
v1 v2 v3 v4
ADC1 0.47 -0.57 -0.12 -0.66
ADC3 0.47 -0.45 -0.12 0.75
rCBV1 0.55 0.63 -0.54 -0.05
rCBV3 0.50 0.26 0.82 -0.02
λ (10−2) 3.14 1.51 0.72 0.22
variance explained 56% 27% 13% 4%
with the different image and target ROI combinations detailed in table 4.1. Figure
4.7 shows the distribution of PRM and MPRMv2 fractional volumes among respond-
ing (R, OS ≥ 18.2 months) and non-responding (NR, OS < 18.2 months) patients.
Only the class (i.e. increasing, decreasing, no change) which was found to maximally
separate the NR and R patients groups is shown for each of the 12 analyses.
Fractional volume measures were found to be significantly different (p < 0.05,
Wilcoxon rank sum test) between R and NR patient groups for the P7 (PRMrCBV ,
PERIPH, no blurring), M2 (MPRM, CEL, blurring), M3 (MPRM, PERIPH, no
blurring), and M4 (MPRM, PERIPH, blurring) analyses. p-values for analyses P1
(PRMADC , CEL, no blurring), P5 (PRMrCBV , PERIPH, no blurring), and M1 (MPRM,
CEL, no blurring) were found to be 0.08, 0.07, and 0.07 respectively while p ¿ 0.1 for
the remaining analyses. However, it should be noted that a total of three statistical
tests were performed for each of the analyses shown in figure 4.7 in order to select
and subsequently show the class (increasing, decreasing, no change) which maximally
separated the responding and non-responding patients. Upon applying a Bonferroni
correction to correct the significance level for multiple comparisons, fractional volume
measures were only found to be significantly different for analyses M2, M3, and M4.
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Figure 4.7: Summary of (a) CEL and (b) PERIPH analyses from table 4.1. The distri-
bution of fractional target volumes classified as increasing (red boxplots), decreasing
(blue boxplots) or not changing (green boxplots) for the non-responding (NR, OS <
18.2 months) and responding (R, OS ≥ 18.2 months) patient groups are shown. Only
the class which maximally separated the NR and R patients groups is shown for each
analysis. Error bars encompass the central 95% of each distribution. Each pair of
boxplots is labelled according to the analyses described in table 4.1.
ROC analyses were applied to each of the distributions in figure 4.7 for which p <
0.1 in order to predict OS ≥ 18.2 months. For prediction, a simple threshold approach
was employed whereby patients were classified as responders or non-responders ac-
cording to whether their fractional volume measures were above or below a cut-off
value which was varied in the ROC analysis. Figure 4.8 shows the ROC curves and
indicates the area under the curve (AUC) values for each analysis.
Similar to the analysis of the fractional volume distributions in figure 4.7, only P7,
M2, M3, and M4 ROC analyses were found to be significantly predictive of OS ≥ 18.2
months (p < 0.05). p-values for analyses P1, P5, and M1 were found to be 0.07, 0.06,
and 0.06 respectively. Table 4.3 provides an overview of the classification performance
for the four significant ROC analyses. Maximum sensitivity, specificity, and accuracy
values are reported in table 4.3 and correspond to the points on the figure 4.8 ROC
curves that are closest to the top left corner of the ROC plots. Fractional volume cut-
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off thresholds for analyses M3 and M4 were both 1% suggesting that non-responding
patients do not tend to exhibit decreases in multi-parametric intensity values within
PERIPH as evaluated in the direction of the second reference PC.
Figure 4.8: Prediction of OS ≥ 18.2 months based on (a) CEL and (b) PERIPH
fractional volume distributions from figure 4.7. * indicates AUC values that are
significantly different from 0.5 at the p = 0.05 level.
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Table 4.3: Summary of classification performance for the statistically significant ROC analyses in figure 4.8. The fractional
volume cut-off value (fx vol cut-off) which produced the reported maximum classification sensitivity, specificity and
accuracy is also shown.
Analysis Method Data Target IRE blurring Class Fx vol cut-off Sens (%) Spec (%) Acc(%) AUC
P7 PRM rCBV PERIPH no dec 0.50 70 89 79 0.78
M2 MPRM all CEL yes nc 0.93 90 78 84 0.82
M3 MPRM all PERIPH no dec 0.01 80 78 79 0.83
M4 MPRM all PERIPH yes dec 0.01 90 78 84 0.84
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4.4 Discussion
The development of effective treatment response prediction is an essential step on
the path towards personalized cancer treatment. PRM analysis has been shown to
be predictive of early treatment response within many contexts [2–7] and may be
advantageous for guiding locally adaptive treatments such as sub-volume boosting.
However, the PRM method has been almost exclusively applied to longitudinally
acquired single-parameter image data. Here, our goal was to present a PRM analysis
framework which enables multi-parametric response prediction while maintaining the
key advantages of the original PRM method. PCA was first applied to the multi-
parametric data within a normal tissue reference ROI. The multi-parametric data
within a target ROI (e.g. tumour) were then projected onto the reference PCs in
order to classify the target data as increasing, decreasing, or not changing according
to the multi-parametric variance within normal tissue reference ROIs.
The key advantages of the original PRM method are that it i) takes into con-
sideration the spatial heterogeneity in tumour response through voxel-wise analysis,
ii) enables intuitive visualizations of this heterogeneity and iii) provides an accessi-
ble and effective means of probing image data for treatment response biomarkers.
The MPRM was designed to reproduce these key elements while extending PRM
to the multi-parametric context. Employing PCA, the MPRM classifies each target
voxel according to the combination of all N multi-parametric image intensity values
that are associated with that voxel. That is, each target voxel is classified accord-
ing to its unique position with an N -dimensional coordinate space that is defined
and normalized by the normal tissue reference PCA. In this way the MPRM takes
into consideration the spatial heterogeneity in multi-parametric tumour response. As
shown in figure 4.6, the spatial heterogeneity in multi-parametric tumour response
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can then be intuitively visualized and interpreted via maps generated from each of
the reference PCs. Each map expresses the target data heterogeneity in terms of
the reference data heterogeneity along each PC using PIs. The MPRM algorithm
has also been made publically available via the MATLAB file exchange to mirror the
accessibility of the original method.
The MPRM acts as a filter which re-expresses, distils, and visualizes the N -
dimensional target data in terms of a standardized context of interest. This is advan-
tageous since it can be difficult to directly conceptualize and compare N -dimensional
data. An MPRM built from the first PC of the reference PCA demonstrates the dif-
ference between the multi-parametric target data and the N -dimensional mean of the
reference data along the direction of the first PC. An MPRM built from the second
PC of the reference PCA compares the variability of the target data to variability
of the reference data about the first PC. Further intuition may be obtainable by in-
vestigating the image weights which compose the reference PCs (e.g. table 4.2). For
example, if a reference PC is dominated by a specific image volume and MPRMs built
from that reference PC are predictive, then prediction is largely driven by variation
in the dominant image volume.
While PCA has been discussed and used for different purposes in previous PRM
studies, to our knowledge it has never been employed for the purposes of comput-
ing and applying classification thresholds to multi-parametric image data as in the
present study. Galban et al. [6] applied PRM analysis to registered inspiration and
expiration lung CT scans to evaluate the extent of functional small airways disease
and emphysema among a cohort of patients with COPD. PCA was subsequently
applied to the registered CT scans to demonstrate that airways disease precedes em-
physema in the progression of COPD, however it was not used to compute thresholds
for the PRM analysis. Boes et al. [15] previously suggested that PCA could be used
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to derive single-parameter PRM thresholds from single-session test-retest image data
though this strategy was not employed. Finally, Zha et al. [9] computed a PRM
threshold from PCA of voxel value frequency histograms obtained from registered
inspiration and expiration lung CT scans. In contrast, the MPRM method applied
PCA directly to multi-parametric image data within reference ROIs rather than to
image frequency histograms in order to determine classification thresholds. These
thresholds were then applied by projecting and re-expressing the target data in terms
of the normal tissue variability along the reference PCs. Consequently, target data
variation is defined and classified relative to and in the direction of the reference PCs.
Furthermore, the target data are classified by a series of PI-based thresholds rather
than a single cut-off threshold.
To demonstrate preliminary efficacy, we applied PRM and MPRM analysis to
ADC and rCBV data acquired from a group 19 patients treated for high-grade glioma.
The MPRM with IRE blurring was found to be the only significant predictor of OS
within the CEL. The MPRM was also found to be a significant predictor of OS for
PERIPH analyses both with and without IRE blurring. This result supports the
idea that functional changes in peritumoral regions may be predictive of treatment
response. In comparison, the PRM was only found to be significantly predictive of OS
when applied to rCBV data within PERIPH and without IRE blurring. The MPRM
provided improved prediction of OS when compared to PRM for analysis of both the
CEL and PERIPH ROIs as shown by the increased AUC values in Figure 4.8 and
classification statistics in table 4.3. This further demonstrates the potential benefit
of multi-parametric response prediction and indicates some preliminary utility for the
MPRM method.
The AUC values within this study also compare favourably to Galban et al. [2]
where PRM analysis of rCBV data within the intersecting CEL among 44 patients
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with glioblastoma yielded an AUC of 0.754. Interestingly, in the present study the
fractional volume classified as decreasing in rCBV by the original PRM method was
predictive of OS within the PERIPH region but not within the intersecting CEL as
was the case in the study by Galban et al. [2]. This difference is likely due to our
analysis of 1 and 3-month post-RT data versus the pre-RT and 1-week mid-treatment
data analyzed by Galban et al.[2].
Overall, IRE blurring was found to preferentially improve MPRM analyses while
deteriorating PRM analyses. IRE between image volume pairs of the same image
type (PRM analyses) may be smaller than the IRE between multiple image volumes
of different types (MPRM analyses) and so the IRE blurring kernel may have over-
compensated for the influence of IRE on PRM analyses reducing predictive efficacy.
Alternatively, the use of a zero-mean isotropic blurring kernel (i.e. IRE probability
distribution function) may be better suited for application to multiple images. The
cumulative distribution of IREs among four co-registered images may be less biased
in a single direction (i.e. more isotropic) than for a single pair of images since there
are 6 (4 choose 2) unique pairs of spatial correspondences each with their own IRE
distribution.
There are several limitations to the present study. First, the MPRM is subject
to the limitations of PCA such as sensitivity to data scaling. The first few PCs are
dominated by the primary sources of variation within the data. However large vari-
ations in a specific type of functional image data may or may not be as important
for prediction as small variations in other types of functional image data. Therefore
the MPRM may not be able to capitalize on image data with low variation but high
predictive potential when analyzed alongside other high-variation image data. As a
first step towards minimizing this effect, we first normalized each image volume so
intensity values fell between 0 and 1. While this reduces the differential variance due
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to differing imaging modalities, differential variance will still remain. An alternative
scaling approach could involve standardizing each image volume using the mean and
standard deviation of the image intensity values within the reference ROI (i.e. com-
puting z-scores). This would ensure that the reference data in each image volume
has zero mean and unit standard deviation. In a follow-up analysis we used this
alternative scaling method and found that MPRMs built from the fourth PC were
predictive of OS with AUC values of 0.83 and 0.79 for CEL and PERIPH analyses
respectively.
For clarity we primarily investigated the predictive utility of MPRMs built from
the second PC of the reference PCA. However, MPRMs built from higher order PCs
could also be useful for response prediction. For example in figure 4.6, MPRMv4 also
appeared notably different between the patients with long and short OS suggesting
that MPRMv4 may have possessed some predictive utility. Our follow-up analyses
which used the alternative scaling procedure also suggested that maps built from
the fourth reference PC were predictive. Ultimately, PCA is a purely descriptive
technique and does not reveal the directions of multi-parametric image variance which
maximally distinguish between responding and non-responding patients. Therefore,
there is no a-priori reason to expect that MPRMs built from different reference PCs
will be more or less predictive than one another. A maximally predictive direction
could potentially be obtained through regressing the reference PCs on the outcome of
interest (e.g. overall survival) using a technique called principal component regression.
This direction (vector), defined by a linear combination of the reference PCs, could
then be used to produce a single MPRM for each patient. The incorporation of
principal component regression into the MPRM framework will be the primary focus
of future development.
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In addition to comparison with the original PRM method, we could have com-
pared the predictive utility of our method to the bivariate logistic regression approach
that was used by Galban et al. [8] to combine independent PRM response biomark-
ers. However, our investigations in figures 4.7 and 4.8 revealed that there were no
statistically significant PRM response biomarkers for analysis of the CEL and only
one significant PRM biomarker for PERIPH. Therefore we omitted a comparison
with this bivariate logistic regression approach as there were no pairs of statistically
significant PRM biomarkers to combine within the present study.
Finally, our preliminary demonstration of MPRM efficacy involved analysis of
a relatively small number of patients (n = 19). However, this patient number is
consistent with another preliminary PRM study [4] and we also employed leave-one-
out cross-validation during predictive analyses to mitigate over-fitting. Nonetheless,
the predictive efficacy of the MPRM method should still be verified among larger
patient populations.
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4.5 Conclusion
We have proposed a generalized approach towards multi-parametric response map-
ping using principal component analysis which preserves the key advantages of the
original PRM method within the multi-parametric context. The algorithm takes
into consideration the spatial heterogeneity in multi-parametric response, supports
intuitive visualizations and interpretation, and was also made publically available to
improve accessibility. The MPRM was shown to be significantly predictive of overall
survival amongst a group of patients treated for high-grade glioma and also offered
improved prediction compared to single-parameter PRM analyses suggesting the po-
tential benefit of multi-parametric response prediction using the MPRM.
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Chapter 5
Conclusion and Future Work
5.1 Summary of findings
5.1.1 Radiation dose-response relationships for liver tumours
Radiation-dose response relationships define the probability of tumour control as a
function of prescribed radiation dose. An improved understanding of these relation-
ships could help to adapt dose prescriptions to patients (i.e. personalize) in order to
improve tumour control or reduce side-effects. Chapter 2 contributed to this body
of knowledge by defining dose-response relationships for patients treated with SBRT
for hepatocellular carcinoma (HCC) and colorectal liver metastases (MET). To our
knowledge, this study was the first to explicitly model dose-response relationships for
HCC patients and the second to do so for MET patients [1]. 50% and 90% probabil-
ities of 6-month local control were estimated to be achievable by 2 Gy per fraction
equivalent doses (α/β = 10Gy) of 53 Gy and 84 Gy for the HCC group and 70 Gy
and 95 Gy for the MET group, respectively. Results for the MET group also helped
to support a previously reported MET dose-response relationship [1]. Overall, we
found that a higher radiation dose was required to control MET tumours when com-
pared to HCC and that RT provided improved tumour control for HCC patients when
142
compared to MET patients at our institution.
5.1.2 Augmented parametric response mapping
Guidance of next generation locally adaptive radiotherapy techniques such as sub-
volume boosting requires image-based treatment response prediction. The PRM is an
image-based method for prediction of overall treatment outcome (e.g. overall survival)
which shows promise as a tool for guiding personalized locally adaptive radiotherapy
(RT). However, image registration error (IRE) introduces uncertainty into this voxel-
wise analysis technique which may limit its use for guiding RT. Chapter 3 proposed
an augmented PRM method (A-PRM) to address this challenge. The original PRM
method was extended to include an IRE-related PRM analysis confidence interval and
also incorporated multiple graded classification thresholds to facilitate visualization.
PRM and A-PRM analyses of CT-perfusion functional images with known simulated
IRE were compared to analysis without simulated IRE to investigate the two methods
in the presence of controlled IRE. The A-PRM was shown to help visualize and
quantify IRE-related analysis uncertainty. The use of multiple graded classification
thresholds also provided additional contextual information which could be useful for
visually identifying adaptive RT targets (e.g. sub-volume boost regions). The A-PRM
should facilitate reliable PRM guided adaptive RT by allowing the user to identify if a
patient’s unique IRE-related PRM analysis uncertainty has the potential to influence
target delineation.
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5.1.3 Multi-parametric response mapping
Voxel-wise analysis of functional imaging acquired at two time points using the PRM
has been shown to be an effective tool for early prediction of cancer treatment out-
comes (e.g. overall survival) and may also be well-suited towards guiding personalized
locally adaptive RT. However, the PRM method has been designed for and almost ex-
clusively applied to analysis of longitudinally acquired pairs of single-parameter image
data. Chapter 4 proposed a novel approach towards multi-parametric response map-
ping (MPRM) to address this challenge. The overall objective was to improve global
treatment response prediction (e.g. overall survival) and facilitate future investiga-
tions into voxel-wise response prediction for guidance of locally adaptive RT. MPRM
analysis was applied to a multi-parametric dataset acquired from a group of n = 19
patients treated for high-grade glioma with comparisons to original single-parameter
PRM analysis. Separate PRM and MPRM analyses of the contrast-enhancing lesion
(CEL) and 1 cm of peripheral tissue (PERIPH) were performed. The original single-
parameter PRM was found to be significantly predictive of median overall survival
only when applied to rCBV data within the PERIPH ROI (AUCPERIPH = 0.78, p <
0.05). The MPRM was found to be significantly predictive of median overall survival
for both CEL and PERIPH analyses and offered improved prediction (AUCCEL =
0.82, AUCPERIPH = 0.84, p < 0.05) suggesting the benefit of multi-parametric re-
sponse prediction using the MPRM. The significant predictions of OS for PERIPH
analyses also supported the idea that functional changes in peritumoral regions can be
predictive of treatment response. In summary, the proposed algorithm accounted for
spatial heterogeneity in multi-parametric response, supported intuitive visualizations,
and was found to improve prediction of overall survival. To mirror the accessibility of
the original PRM method, the MPRM algorithm was also made publically available
via the MATLAB file exchange.
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5.2 Limitations and Future Work
5.2.1 Radiation dose-response modelling
There are several key limitations to the dose-response study in Chapter 2. First,
tumour control probability was modelled with respect to an endpoint of 6-month local
tumour control. Due to patient-specific variability in follow-up scheduling, the tumour
control endpoint was evaluated within a 6-month ± 1 month interval introducing
uncertainty into our dose-response analysis.
This 6-month endpoint was appropriate for the patients with colorectal liver
metastases since their median time to loss of local control was found to be approxi-
mately 6 months (183 days). 1-year local control has also previously been reported
to be approximately 60% among this demographic [1]. However for HCC tumours,
studies have reported 1-year local control rates of greater than 90% suggesting SBRT
provides 6-month local control for most patients [2]. Therefore a modelling endpoint
of 1-year local control or greater may be more beneficial to the community for in-
forming HCC SBRT dose prescriptions. In our cohort of HCC patients, a 1-year local
control rate of 65% was observed, lower than those reviewed by Dawson et. al. [2].
This could be due to the fact that more advanced HCC patients were referred for ra-
diotherapy when tumours occupied a larger fraction of the liver, limiting our ability
to prescribe higher dose without risking treatment-related toxicities.
While we demonstrated in Chapter 2 that there is a relationship between radiation
dose and 6-month tumour control for primary and metastatic liver tumours, patients
included in the study had a range of dose-fractionations and were not uniformly
treated with SBRT type doses. Dose fractionations ranged from 2-10 Gy/fraction with
a median of 4 Gy /fraction. Therefore the dose-response relationships determined in
Chapter 2 could differ from those among a patient demographic treated with more
145
uniform dose-fractionations. Nonetheless, this study helps to motivate future dose-
response studies.
Another limitation in Chapter 2 is that when imaging data were unavailable,
tumour control was assessed using blood-based measurements of alpha-fetoprotein
for HCC and carcinoembryonic antigen for colorectal cancer as surrogates for tumour
response. While the utility of these measurements for assessing tumour response has
been previously demonstrated [3, 4], direct imaging based measurements would have
been preferable to access local control information in order to maintain consistency
within the study.
The incidence of hepatocellular carcinoma in Canada and the United States is
rapidly increasing [5, 6]. Therefore, investigation of radiation dose- response rela-
tionships for HCC could have an increasingly positive impact on cancer treatment.
While the study in Chapter 2 provided some insight into these relationships, larger
studies are needed to verify the single-institution trends that were observed. That
is, multi-institution dose-response studies such as the one performed by Chang et al.
[1] for colorectal liver metastases need to be undertaken to validate the dose-response
relationship for HCC.
5.2.2 Augmented parametric response map
One of the primary limitations of the A-PRM method proposed in Chapter 3 relates
to the use of a spatially invariant 3-dimensional Gaussian distribution to model the
image registration error probability distribution function. First, the probability of
IRE is lower near salient image features (e.g. edges, high-contrast regions) and higher
away from these features and so IRE is spatially variable. Therefore in the future the
A-PRM would ideally incorporate a spatially varying IRE PDF to more accurately
describe this uncertainty. A first approach could involve spatially modulating the
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width of the Gaussian IRE PDF according to multiple point estimates of the IRE
throughout the analyzed ROI obtained from inspecting the positions of corresponding
fiducials.
Second, while the width of the Gaussian IRE PDF could be customized, ulti-
mately it represents a simplified first order approach towards describing IRE. IRE
can vary in complex non-rigid ways and cannot be fully captured by this approach.
In the future, incorporation of empirically determined IRE PDFs may be beneficial.
Bootstrapping and probabilistic image registration frameworks which simultaneously
estimate a registration solution and registration uncertainty [7, 8] could potentially
be used to improve definition of the IRE PDF in this way. This approach may have
the added benefit of not requiring the user to provide an explicit estimate of an IRE
upper bound for each patient as was the case in Chapter 3.
The demonstration of the A-PRM involved measurements of the differential im-
pact of simulated rigid IRE on voxel classification between the PRM and A-PRM
methods. However in the future, the A-PRM should be applied to larger image
datasets with verified predictive utility using PRM analysis. Both rigid and non-rigid
IRE would be simulated in the image data and then the impact of IRE on both voxel
classification and prediction of global treatment outcomes such as overall survival
would be compared between the PRM and A-PRM methods. This approach would
provide a more complete assessment of the impact of integrating IRE uncertainty into
PRM analysis.
5.2.3 Multi-parametric response map
There are several important limitations to the MPRM study and associated areas
for future work that should be discussed. First, our demonstration of efficacy in-
volved analysis of a multi-parametric image dataset acquired from patients treated
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for glioblastoma at 1 and 3-months post-RT. While predictive utility was demon-
strated using this data, ideally the MPRM would be applied to a dataset which has
already been shown to have predictive potential using the original PRM method. For
example, application to ADC and rCBV functional images acquired before and during
RT may better elucidate the potential benefit of MPRM prediction compared to the
original PRM. Moreover, since the ultimate goal of this work is to provide tools for
guiding locally adaptive RT, the MPRM should be applied to pre and intra-treatment
image data to demonstrate response prediction during treatment. We did not per-
form a similar analysis in Chapter 4 because pre-treatment MRI was acquired prior
to surgery and radiotherapy rather than after surgery but prior to radiotherapy.
Second, the MPRM is subject to the limitations of PCA. For example, PCA
is sensitive to the scaling of input data. The first few PCs are dominated by the
largest sources of variation within analyzed multi-parametric dataset. Therefore the
MPRM cannot take advantage of image data with high predictive potential but low
variability when analyzed alongside other image data with high variability. In the
future, alternative scale-invariant forms of PCA could be integrated into the MPRM
method [9]. However, in a follow-up analysis we found that standardizing each image
by the mean and standard deviation of the reference ROI image intensities could offer
a simpler approach. PCA also does not add value for analysis of highly uncorrelated
image data since resulting PCs would fall along the original axes defined by each
of the input images. Therefore the MPRM may be best suited towards analysis of
longitudinally acquired image data where two or more images of the same type (i.e.
highly correlated images) are included in analysis.
Finally, only MPRMs built from classification along the second PC of the refer-
ence PCA were primarily investigated for predictive utility in Chapter 4. MPRMs
built from other PCs could have predictive value and should also be investigated.
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Ideally, the MPRM should be improved in the future to produce a single response
map or include an algorithm for selecting a single map most likely to have predic-
tive potential. One approach towards building a single map could involve combining
classifications along multiple reference PCs. For example, each voxel could be clas-
sified by the L2-norm (square root of the sum of each vector component squared) of
its PI-based coordinates along multiple PCs. Alternatively, a single map could be
selected for investigation by performing a second PCA on the target data. MPRMs
could be built from the reference PC that most closely matches the direction of the
first PC from the target PCA. This would ensure that MPRMs are built from the
reference PC which maximally stratifies target data variation. However, both of these
alternative approaches would not guarantee that the resulting MPRMs were built in
a direction which maximally distinguishes responding and non-responding patients.
Such a direction could potentially be found using principal component regression to
determine a linear combination of the reference PCs along which MPRM analysis
would maximally separate responders and non-responders.
5.2.4 Verifying the predictive utility of A-PRM and MPRM
The A-PRM and MPRM methods need to be applied to other functional image
datasets to verify broader predictive utility and search for new biomarkers of treat-
ment response. For example, a previous study has reported PRM predictive utility
based on analysis of repeat arterial phase contrast-enhanced CT imaging of patients
treated with trans-arterial chemoembolization for HCC [10]. A similar study could be
performed using A-PRM analysis of arterial-phase imaging for patients treated with
SBRT for HCC.
Parametric response maps predict global measures of response like overall survival
based on voxel-wise image analysis. PRMs also indicate the tumour voxels associated
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with this prediction. However, it has not yet been verified whether tumour voxels as-
sociated with a prediction of global response actually respond in a local sense. That is,
do tumour sub-regions associated with prediction of favourable global response disap-
pear after treatment? Conversely, do tumour sub-regions associated with prediction
of unfavourable global response remain or grow after treatment? These relationships
may need to be confirmed prior to using PRM methods (including the A-PRM and
MPRM) to guide locally adaptive treatments such as sub-volume boosting or dose-
painting by numbers. Such a study would require functional imaging of a patient
group with which to make predictions and then frequent anatomical imaging during
and after treatment to monitor changes in tumour size and shape.
5.2.5 Evaluating feasibility of response map guided radio-
therapy
Once predictive utility has been verified, studies should be performed to investigate
the technical feasibility of delivering radiation to adaptive RT targets defined by
parametric response maps. These studies would be similar to the planning feasibility
studies performed for hypoxia-guided RT dose escalation [11]. Adaptive RT plans
would be generated for a cohort of patients based on a set of PRMs which have been
shown to be predictive of treatment response. The planned dose to conventional
targets, adaptive targets, and normal tissue would be reported for each patient to
assess whether PRM-guided adaptive RT is feasible using current treatment planning
and delivery systems. Depending on availability, TCP and NTCP models could also
be used to estimate the impact of adaptive treatment on tumour control and normal
tissue toxicity.
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5.2.6 Treatment response prediction software tools
User-friendly image-based treatment response prediction software should be devel-
oped to encourage the broader use and clinical translation of the methods discussed
in Chapters 2 and 3. The A-PRM and MPRM methods could be integrated into
existing open-source frameworks such as 3D Slicer [12].
For example, an A-PRM module could incorporate slider bars in each of the
three coordinate directions to allow the user to easily adjust the amount of IRE they
anticipate within their analysis. Such a feature would be accompanied by real-time
updates to A-PRM visualizations. This would allow the user to quickly probe patient-
specific analysis uncertainty due to IRE and take steps to account for its impact on
delineation of adaptive RT targets. The MPRM could be similarly incorporated into
an analysis module.
As discussed in §4.4, the MPRM acts as a filter which re-expresses, distils, and
visualizes N -dimensional multi-parametric data in terms of a standardized context of
interest (i.e. the reference PCA). Therefore a user-friendly software implementation
of the MPRM could also be advantageous for general exploration and description of
multi-parametric data. An open-source library of reference PCAs (i.e. eigenvectors
and eigenvalues) could be populated from MPRM analyses of different combinations
of multi-parametric imaging, cancer types, and reference ROIs. Other investigators
could then use these reference PCAs to build MPRMs for the purposes of analyzing
individual patient’s multi-parametric data within standardized frames of reference.
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a. EDUCATIONAL BACKGROUND 
 
Degree Specialty / University Research Years Active  
PhD, 
MSc-CL 
CAMPEP 
Medical Biophysics,  
University of Western 
Ontario (UWO) 
 
Image-based treatment response 
prediction; towards guidance of 
locally adaptive radiotherapy 
Supervisor: Dr. Eugene Wong 
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MSc Medical Biophysics, 
University of Toronto 
 
Deformable image registration for 
dynamic contrast-enhanced MRI 
Supervisor: Dr. Anne Martel 
 
2009 - 2011 
BSc Mathematical Physics,  
Co-operative Program, 
University of Waterloo 
Projects summarized in section  
f. Research assistantships 
2004 - 2009 
b. PUBLICATIONS 
 
    i. Refereed journal articles 
 
           A Lausch, A Ward, S Gaede, J Chen, TY Lee, E Wong.  An augmented parametric   
           response map with consideration of image registration error: towards guidance of locally   
           adaptive radiotherapy.  Phys Med Biol 2014;59:7039-7058 
 
           A Lausch, K Sinclair, M Lock, B Fisher, N Jensen, S Gaede, J Chen, E Wong.   
           Determination and comparison of radiotherapy dose response for hepatocellular  
           carcinoma and metastatic colorectal liver tumours.  Br J Radiol 2013;86:20130147  
           (“Top CCS-funded research stories, 2013”)         
 
           Ebrahimi M, Lausch A, Martel A.  A Gauss-Newton approach to joint image registration   
           and intensity correction. Comput Methods Programs Biomed 2013;112:398-406 
 
           S. Wesolkowski, A Lausch (2010) Validation of the stochastic fleet estimation model.   
           DRDC-CORA TM 2010-042  
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  ii. Refereed conference proceedings  
                
          A Lausch, T.P.C Yeung, E. Fainardi, T.Y. Lee, J. Chen, E. Wong. Can parametric   
          response maps predict voxel-wise treatment response?  Implications for locally adaptive   
          radiotherapy. 2015 World Congress on Medical Physics and Biomedical Engineering.      
          Toronto, Canada. (4 pages; oral presentation) 
 
           A Lausch, NKG Jensen, J Chen, TY Lee, M Lock, E Wong. Effects of registration error    
           on parametric response map analysis: a simulation study using liver CT-perfusion    
           images. Proc. 17th International Conference on the Use of Computers in Radiation   
           Therapy. J Phys: Conf. Ser. 2014;489:012032 (5 pages; oral presentation) 
 
           A Lausch, NKG Jensen, J Chen, TY Lee, M Lock, E Wong. Graded-threshold parametric   
           response maps: towards a strategy for adaptive dose painting. Proc. 17th International   
           Conference on the Use of Computers in Radiation Therapy. J. Phys.: Conf. Ser.   
           2014;489:012031  (5 pages; poster presentation) 
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           Biomedical Imaging: From Nano to Macro, pp 561-565, March 30, 2011- April 2, 2011,   
           DOI 10.1109/ISBI.2011.5872469 (5 pages; poster presentation) 
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Lausch A,  Sinclair K, Lock M, Fisher BD, Jensen N, Gaede S, Chen J, Wong E.  
 Evaluation of dose response for radiotherapy of primary and metastatic liver cancer.     
            Canadian Association of Radiation Oncologists 26th Annual Scientific Meeting, Sept 12-  
            15, 2012, Ottawa, ON. Radiother Oncol 104:S2; p 20  (poster presentation) 
 
 Lausch A, Lock M, Ash R, Venkatesan V, Bauman G, Wong E.  Automated conformal   
            avoidance targeting for post-prostatectomy patients. CARO-COMP conference, OCT 09-  
            13, 2007, Toronto, Canada.  Radiother Oncol 85:S69, A241 (poster presentation)  
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CAMPEP PhD MSc-CL Program Steering Committee 
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Member, Communications Committee           2013 
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BIOPHYS 9520B – Practical Medical Imaging, UWO                    Jan. 2014 – Apr. 2014 
 
Summary: Member of eight student team who developed graduate department’s new medical 
imaging lab course based on desktop CT, US, and MRI systems.  On a weekly basis, team also 
researched and discussed effective pedagogy under the direction of a faculty member.   
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BIOPHYS 9700 – Biophysics Graduate Seminar Course, UWO                  2013               
 
Summary: Developed and presented initiatives for improving the graduate seminar program and 
creation of a seminar course.  Organized, chaired, and contributed to subsequent development 
meetings.  Created new seminar evaluation forms.  Course initiated in Sept 2013.  
 
ii. Graduate Teaching Assistantships  
 
BIOPHYS 9700 – Biophysics Graduate Seminar Course, UWO                  Sept 2013 - July 2014 
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Physics Research Assistant, Physics Department                                    May 2009 - Aug. 2009 
London Regional Cancer Program, London, ON 
Supervisor: Dr. Eugene Wong 
Project/Task Summary:  Continued development/testing of a computer assisted target definition 
algorithm for prostate bed radiotherapy.   
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Department of National Defence, Ottawa, ON 
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to military transport missions. 
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London Regional Cancer Program, London, ON 
Supervisor: Dr. Eugene Wong 
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Quality Assurance, Physics Department               Sept. 2014 - Dec. 2014  
London Regional Cancer Program, London, ON                                        Sept. 2013 - Dec. 2013 
Performed basic quality assurance checks and output                               Sept. 2006 - Apr. 2007  
measurements for Varian Clinac iX and TrueBeam 
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